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AND THEIR TARGETS 
 
Sarah Anne Wacker 
The Rockefeller University 2012 
 
Bioactive small molecules are valuable tools to understand and 
manipulate biological pathways. In order to be effective as either probes for 
understanding cell biology or as clinical drugs, the small molecule’s mechanism 
of action must be characterized. However, identifying a small molecule’s target 
and characterizing its interaction with that target remain major challenges in the 
chemical biology field. In this thesis, I describe methods to improve the process 
of drug target identification and binding site characterization.   
In order to identify the target of a small molecule, I have developed an 
approach in which multiple drug resistant clones are isolated and transcriptome 
sequencing is used to find mutations in each clone. Further analysis of 
mutations common to more than one drug-resistant clone can identify a drug’s 
physiological target and indirect resistance mechanisms. In proof-of-concept 
studies I analyze clones resistant to two cytotoxic anti-cancer drugs, BI 2536 
and bortezomib. For both compounds I detect mutations in the known target 
that confer resistance to the drug. Unlike other target identification methods, 
this approach can establish a genetic proof of the target in human cells.   
I have also developed a method to characterize a small molecule’s 
binding site after its target is known. In this method, called Stable Isotope 
Labeled Inhibitors for Crosslinking (SILIC), structure-activity relationship data is 
used to design inhibitor analogs that incorporate a photo-crosslinking group 
along with either natural or heavy stable isotopes. An equimolar mixture of 
these inhibitor analogs is crosslinked to the target protein to yield a robust 
signature for identifying inhibitor-modified peptide fragments in complex mass 
spectrometry data. I applied this approach to an ATP-competitive inhibitor of 
kinesin-5, a widely conserved motor protein required for cell division. This 
analysis, along with mutagenesis studies, suggests that the inhibitor binds at an 
allosteric site in the motor protein. 
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Introduction: Techniques for target validation 
 
Many bioactive small molecules function by binding to proteins and 
affecting those proteins’ cellular function(s). These small molecules are valuable 
tools to study the proteins on which they act (Peterson and Mitchison, 2002), and 
small molecule “bioprobes” have been successfully used to characterize the roles 
of proteins involved in a multitude of cellular processes. They are especially 
useful to probe protein functions since they act on a fast timescale and their 
effects are frequently reversible (Lampson and Kapoor, 2006).  In addition to 
functioning as tools to study cellular biology, small molecules can be developed 
into clinical therapeutics.  
A clear understanding of the mechanism of action of a small molecule is 
essential if that compound is to function as a research tool or be developed into a 
therapeutic agent. This is especially important for a small molecule bioprobe: if 
the proteins it interacts with are not known, then the compound cannot be used to 
further understand those proteins. It is also advantageous to identify the protein 
targets of a drug as this knowledge informs on its potential clinical efficacy. 
Information regarding a drug’s mechanism of action allows for optimization of the 
drug’s specificity during development and, while the drug is in the clinic, provides 
guidance for potential combination therapies, likely side effects due to additional 
targets, and insight into drug resistance.  
	  2 
The process of connecting small molecules with their cellular targets is a 
major challenge in the fields of chemical biology and drug discovery. This chapter 
will discuss the major methods available for identifying small molecule targets, 
with a focus on the advantages and disadvantages of each technique.  
 
Methods to identify the targets of small molecules 
There are numerous methods that can be used to partially elucidate a 
small molecule’s mechanism of action. Identifying the optimal method to 
determine a drug’s relevant target(s) depends on a number of factors, particularly 
on the organisms in which a drug is active and on the ease with which a drug can 
be chemically manipulated.  Current methods for target identification can be 




A common approach to target identification relies on in vitro readouts of 
protein activity or small molecule binding (Sleno and Emili, 2008). This is how 
cyclophilin was identified as the target of cyclosporine A (Handschumacher et al., 
1984), how the target of FK506 was determined to be FKBP (Harding et al., 
1989), and how histone deacetylases were identified through binding to trapoxin 
(Taunton et al., 1996). Biochemical target identification strategies have been in 
use for decades (Cuatrecasas et al., 1968; Reynolds et al., 1978; Rix and 
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Superti-Furga, 2009) and the basic strategy has benefitted from many technical 
advances. 
 
Affinity chromatography to isolate binding partners 
The proteins that bind directly to a small molecule can be identified 
through affinity chromatography (Figure 1.1). In this method, the small molecule 
of interest is attached to a solid support and then used to “pull-out” binding 
partners from cellular extracts. Typically, the small molecule is immobilized to the 
solid support through a suitable functional group (carboxylic acid, primary amine, 
or hydroxyl group) or linking molecule. This “affinity matrix” is then combined with 
a cell or tissue lysate in order to bind proteins. The affinity matrix is stringently 
washed to remove non-specific binding proteins. Finally the bound proteins are 
eluted from the solid support by denaturation. The eluted proteins are then 
identified, usually by mass spectrometry. 
While biochemical purification of proteins that bind small molecules has 
been useful in the identification of many target proteins, the approach has a 
number of limitations. It can be challenging to generate analogs of a small 
molecule capable of attaching to the support resin, since this generally requires 
addition of a separate functional group to the small molecule. The small molecule 
must be modified in a way that its mechanism of action is unchanged. The small 
molecule must also be fully accessible to all potential target proteins, and this 






Figure 1.1 Schematic highlighting the key steps of affinity chromatography. 
A cellular extract is incubated with an affinity matrix consisting of the small 
molecule of interest (dark green thunderbolt) attached to a support resin (light 
blue circle). The small molecule interacts with proteins. The affinity matrix is 
washed to remove unbound and non-specific proteins. The proteins are eluted 




attachment. Ensuring these two basic requirements is difficult when the 
mechanism of action is unclear and the molecular binding requirements are 
unknown.  
Additional challenges arise during the identification of binding proteins 
from an affinity chromatography experiment. Even with vigorous washing, it is 
difficult to eliminate all non-specific binding proteins. Furthermore, the small 
molecule—target interaction must be of high affinity in order to persist throughout 
the washing steps. Finally, not all targets are soluble in the media used for 
binding and, thus, the relevant binding partners for a small molecule may not be 
amenable to bioinformatics identification. 
To discriminate between real binding partners and non-specific binding 
proteins, the eluted proteins can be compared with those found in a negative 
control sample. Ideally, a non-active small molecule analog is examined in 
parallel with the active small molecule (Oda et al., 2003). Since inactive 
compounds are frequently not available, it is also possible to use the resin alone 
or the solid support with a similar linking group as control conditions. 
Alternatively, chemically distinct molecules may be used to identify and 
deprioritize proteins that frequently appear in affinity chromatography 
experiments. It is also possible to compare proteins eluted after serial binding of 
lysate to the affinity matrix, which assumes that specific binding proteins will be 
the first to be depleted from the lysate (Yamamoto et al., 2006). 
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Even with proper negative controls, it can be difficult to determine whether, 
and by how much, proteins are enriched in the sample containing the active 
compound over the control sample. To more easily discriminate between protein 
levels in the two samples, stable isotope labeling of proteins has been employed 
(Ong et al., 2009). This requires two cell lysate samples: one natural sample and 
the other containing proteins labeled with heavy isotopes. The two protein 
extracts are then incubated with either the drug-bound affinity matrix or the 
negative control. After elution, the samples are combined and processed together 
by mass spectrometry.  As proteins from the heavy isotope sample are heavier 
than proteins from the unlabeled sample by a known mass, this change in mass 
allows proteins associated with the affinity matrix to be easily distinguished from 
proteins that are present in similar levels in the negative control. The addition of 
stable isotopes allows for better detection of low abundance proteins and 
prioritization of more promising candidates because of the quantitative detection 
(Chan et al., 2009). 
Another strategy for identifying target proteins with low abundance or 
which have lower affinity for the drug is by creating covalent attachments 
between the small molecule and its target proteins. This makes it easier to wash 
away non-specific binding proteins without losing real target proteins that are of 
low abundance or have weak association kinetics with the bioactive molecule. 
This approach was useful in identifying the target of the anti-angiogenic 
compound fumagillin (Sin et al., 1997). 
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Activity-based protein profiling 
In addition to affinity-matrix purification of drug binding partners, 
monitoring the activity of potential binding proteins can be used to determine the 
selectivity of a small molecule. Activity-based protein profiling (ABPP), a 
technique originally developed to identify which members of a protein family are 
active (Liu et al., 1999), has been adapted for target identification (Cravatt et al., 
2008). ABPP relies on a probe, separate from the small molecule inhibitor, that 
targets the active site of all proteins in a defined enzyme family. This probe can 
be used to isolate or visualize active members of this family. The technique can 
be used for target identification if the small molecule inhibits proteins so that they 
no longer bind to the active-site-directed probe. By comparing the active proteins 
in a control protein sample with those in a sample pretreated with the small 
molecule inhibitor, one can infer which proteins’ activities have been impacted by 
the drug.  
While ABPP has the benefit of providing information on protein activity, it 
has a number of disadvantages compared with affinity chromatography. ABPP is 
only useful if the general target class is already known. Although ABPP identifies 
how selective a compound is for a given class of enzymes, it does not provide 
any data on unrelated proteins. For enzymes whose activities rely on one 
another, such as kinases in a signaling pathway, it is not possible to know 
whether a protein is inactive because it is directly inhibited by the small molecule 
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or the small molecule inhibited an upstream protein. For these reasons, there are 
limited examples of ABPP being used for target identification (Cravatt et al., 
2008; Leung et al., 2003).  
When a biochemical target identification strategy is successful, a small 
number of specific binding proteins are identified; these proteins must be further 
tested in cells to determine if they are associated with the drug’s biological 
activity. This represents a substantial limitation of in vitro approaches: although 
they can identify direct binding partners, more research is needed before these 
binding partners are associated with the drug’s activity in cells. This limitation is 
magnified by potential discrepancies between the effect of a drug on a protein 
and the phenotype after knockdown of a protein’s levels by RNA interference 
(RNAi) (Weiss et al., 2007). As RNAi is a common method for validating drug 
targets in cells, any discrepancies between the two techniques can lead to 
uncertainty as to the drug’s true target.  Due to its limitations, more scientists are 
using biochemical studies in combination with cell-based approaches to reach a 
greater understanding of drug effectiveness (Rix and Superti-Furga, 2009). Some 
cell-based approaches for target identification are described in the next section. 
 
Chemical Genetics Approaches 
Genetics-based approaches to drug target identification are useful 
alternatives to methods that rely on biochemical techniques which later require 
validation in cells. The concept behind chemical genetics approaches is simple: 
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using a small molecule in combination with genetic perturbations can identify the 
genetic perturbations, and therefore the genes, which suppress or enhance the 
compound’s effects. These genes are likely to be a part of the pathway on which 
the drug acts and may be the drug’s direct target. Since the genes are identified 
in cells based upon a change in responsiveness to the drug, the predicted targets 
are more likely to be physiologically relevant, which is a major advantage 
compared with a biochemical strategy. 
 
Studies in Model Organisms 
Genetic screening in model organisms is a well-established approach for 
drug target identification. The most frequently utilized model organism for target 
identification is the yeast Saccharomyces cerevisiae, for which advanced genetic 
tools are available (Ho et al., 2011).  
One tool for genetic studies in S. cerevisiae is a gene deletion collection of 
~6000 heterozygous diploid and ~5000 viable haploid gene deletion strains 
(Winzeler et al., 1999). Each strain in this library has been tagged with a unique 
twenty base pair sequence that acts as a “molecular barcode.” Thus, strains that 
survive competitive growth assays can be easily identified.  
The yeast gene deletion collection is utilized in haploinsufficiency profiling 
studies (Giaever et al., 1999). These studies are based on the idea that a drug 
will more potently affect organisms that have fewer copies of the target gene.  
This can be the case when the inhibitor prevents a protein from completing an 
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essential role in the cell; thus, if there are fewer copies of the protein that can 
take on this role, less inhibitor is needed to compromise its function. In this 
technique a pool of bar-coded heterozygous yeast strains are grown 
competitively in the presence of a drug. After growth selections, DNA microarrays 
are used to identify the strains with compromised growth in the presence of the 
drug (Giaever et al., 1999; Ho et al., 2011).  These strains are likely to be 
haploinsufficient for genes that encode proteins targeted by the small molecule of 
interest.  
Like many genetics-based approaches, haploinsufficiency profiling can 
identify both direct drug targets and other components of the relevant signaling 
pathways. Furthermore, the method is unbiased if the drug inhibits growth. 
However, haploinsufficiency profiling is unlikely to be effective in identifying drug-
binding partners whose function is not impaired by the compound of interest. 
Additionally, not all target genes are more sensitive to a compound when only 
one of two gene copies is deleted. In these cases a more severe reduction in 
target gene expression may be necessary. 
While haploinsufficiency profiling identifies gene deletions that further 
impair cells after drug treatment, other strategies identify genes that, when 
overexpressed, decrease the potency of a particular compound (Figure 1.2) 
(Luesch et al., 2005). An example of this strategy examines the growth after drug 
treatment of pools of yeast overexpressing different proteins. This method can 





Figure 1.2 Schematic highlighting the key steps of yeast overexpression 
approaches. A collection of yeast strains, each containing an extra copy of a 
different gene, are treated with the small molecule of interest at a concentration 
that impairs the growth of normal yeast. Yeast containing an additional copy of 
the small molecule’s target may grow better than wild type yeast in the drug. 
Plasmids are isolated from all yeast strains and genes that conferred a growth 
advantage are more abundant. These genes are identified through hybridization 
to microarrays.  
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pathway, as was the case for the drug rapamycin (Butcher et al., 2006). As with 
gene deletion studies, this basic approach is limited when changes in gene 
dosage do not impact the efficacy of a small molecule. Furthermore, a large 
number of candidate genes are often identified. 
Forward genetic studies, in which unknown mutations that alter 
responsiveness to a drug are selected for and characterized, have also been 
highly valuable for drug target identification. During a forward genetics screen, 
random mutations are commonly introduced into the genome and mutants that 
are resistant to the drug are selected. This approach was used to identify the 
target of rapamycin (TOR) proteins TOR1 and TOR2 and to demonstrate that 
resistance to rapamycin can occur through mutations in TOR1 and TOR2, along 
with FPR1 (Heitman et al., 1991). The method is unbiased and can identify a 
variety of types of mutation (for example, gene deletion or single nucleotide 
variations). This strategy is especially advantageous because specific mutations 
are often identified that, if shown to cause resistance to the target in vitro, provide 
strong evidence for a direct target (the gold standard in the field).  
The yeast three-hybrid (Y3H) approach takes advantage of model 
organisms but is able to identify proteins that directly bind a small molecule of 
interest (Licitra and Liu, 1996). The Y3H system is a variation on the technique of 
yeast two-hybrid, adapted to identify drug-protein interactions. As its name 
suggests, Y3H requires a third component: the drug is linked to a ligand that 
brings together the two protein molecules. When a protein binds to the small 
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molecule of interest, the proximity of a transcriptional activator, which is linked to 
the drug-binding protein, results in transcription of a reporter gene. 
The Y3H approach has several advantages. Diverse cDNA libraries from 
different organisms (or tissues) can be examined with the approach. It is possible 
to directly identify the binding partners of the small molecule.  Moreover, unlike 
biochemical affinity-based methods, proteins of low abundance or that have weak 
affinity for the small molecule can be identified.   
There are also challenges associated with the Y3H approach. As the 
technique relies on a derivative of the drug that is linked to a ligand, the design 
and synthesis of this molecule may require a substantial research investment. As 
yeast frequently have high levels of multi-drug resistance, the intracellular 
concentration of many small molecules is reduced, decreasing the sensitivity of 
the method. Many false positives are identified in Y3H; thus, it can be challenging 
to identify which of the “hits” represent real interactions. 
Recent methodological advances have overcome some disadvantages of 
the Y3H approach. In order to increase the effective intracellular concentration of 
the drug, S. cerevisiae strains have been created with decreased levels of multi-
drug pumps (Kolaczkowski et al., 1998). The number of false positives has been 
reduced by identifying cells with contaminating plasmids and by checking for 
spontaneous conversion of bait proteins into transcriptional activators (Vidalain et 
al., 2004). Using a SNAP-tag system allows for the Y3H drug derivative to also 
be tested by affinity chromatography, providing validation of binding partners 
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(Chidley et al., 2011). Using these methods, the target of the anti-inflammatory 
drug sulfasalazine was identified (Chidley et al., 2011). 
Some studies combine multiple genetics methodologies for more robust 
target identification. For example, combining deletion and overexpression 
libraries allowed Hoon and coworkers to better understand the mechanism of 
action of two protein phosphatase inhibitors, as each technique further narrowed 
down the potential targets (Hoon et al., 2008). Likewise, Ho and coworkers made 
use of both gene overexpression and forward genetics methods, by creating a 
library of open reading frames to complement and identify mutated genes that 
result in drug resistance (Ho et al., 2009). This technique allowed for the 
identification of drug-resistant mutations in the target of theopalauamide, a 
natural product with potent antifungal activities (Ho et al., 2009). In addition to S. 
cerevisiae, other model organisms are becoming useful for target identification 
studies, including S. pombe (Nishimura et al., 2010), bacteria (Pathania et al., 
2009), and C. elegans (Burns et al., 2006; Kaletta and Hengartner, 2006). 
Chemical genetic approaches in model organisms have been useful for a 
number of case studies and are ideal ways to study drugs that target these 
organisms.  A major limitation of studies in model organisms, however, is the 
potential for divergence between their target proteins and those which exist in 
humans. This divergence exists both in the types of targets (many human 
proteins do not have homologs in S. cerevisiae and other organisms) and in the 
sequence of the targets (because of variation in amino acid sequence among 
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clear homologs, some drugs are not effective against both yeast and human 
counterparts). Another drawback is that for many drugs, particularly anti-cancer 
agents, the relevant setting is a diseased state. This suggests that important 
targets may not exist in the model organism. Finally, as yeast have high 
expression of drug pumps, many small molecules do not effectively get into these 
organisms. 
It is possible to overcome some of these challenges. For example, targets 
from the relevant species can be expressed in model organisms (Arnoldo et al., 
2008). Alternatively, some human diseases can be mimicked in other organisms 
before screening for drug targets (Hartwell et al., 1997). However, there has been 
a recent push to conduct more target identification studies in human cells. 
 
Techniques using human cells 
Due to the biology of human cells and the human reproductive system, 
along with the complexity of the human genome, there are not as many genetic 
resources available for studying human cells as there are for model organisms. 
Thus, target identification studies using human cells are relatively few. 
Nevertheless, several new technologies have been developed and it is likely that 
these approaches will rapidly alter the chemical biology field.  
Whole-genome transcript profiling is one of the more promising target 
identification techniques available for studying compounds in human cells. The 
method is based on the idea that if drugs have common mechanisms of action, 
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then they are likely to produce similar effects on cells. Likewise, if a drug inhibits 
a protein, genetic deletion of that protein may have a similar effect (Lehar et al., 
2008). By matching the transcriptional pattern of cells after treatment with many 
small molecules, it should be possible to group compounds that elicit similar 
effects. These groups will then suggest families of compounds that act on the 
same pathways. An early example of this strategy was conducted in yeast 
(Hughes et al., 2000). Databases of the effects of chemical treatment were used 
to identify cellular pathways affected by drug treatment. These pathways could 
be determined by pattern matching, even in some cases when the effect was 
very subtle (Gunther et al., 2003).  
The most comprehensive pattern-matching project to date is the 
Connectivity Map database at the Broad Institute (Lamb et al., 2006). This 
method has been used in several studies, including identifying HSP90 as the 
target of gedunin and celastrol (Hieronymus et al., 2006). This project conducted 
high-throughput screening of various human cells treated with small molecules or 
genetic perturbations (e.g. RNAi or genetic ablation). The transcriptional profiles 
of the effects of these perturbations were recorded and have been stored in a 
public reference catalog. Importantly, data collected by the Connectivity Map was 
obtained in a manner meant to reduce experimental variability, which is a 
common limitation of transcriptional profiling methods (Lamb, 2007; Lamb et al., 
2006). This database can now be queried to identify agents (either genetic or 
chemical) that result in a similar pattern of gene expression as the compound of 
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interest. This leads to hypotheses of how the small molecule may act, based 
upon the known function of the genes and small molecules profiled in the 
Connectivity Map database. 
Compared to other approaches, such as affinity chromatography, the 
Connectivity Map has both advantages and disadvantages. The proteins and 
pathways resulting from transcriptional profiling are physiologically relevant in 
human cells, which is not possible for biochemical approaches. However, the 
transcriptional data in the Connectivity Map typically represent networks of many 
proteins and translating the hits to a specific protein target is challenging. 
Another difficulty is that not all compounds elicit transcriptional changes. For 
those small molecules that do result in a unique transcriptional profile, there may 
not be a compound or genetic perturbation in the database that creates a similar 
effect. Until more agents are analyzed and cataloged, this will likely be a major 
challenge.  
In order to expand the applicability of pattern-matching there has been a 
call to couple transcriptional profiling with other cellular responses (Feng et al., 
2009).  Methods, such as high-throughput microscopy, have been successfully 
used to characterize the dose-dependent effects of diverse small molecules on 
multiple cancer cells (Perlman et al., 2004).  The resulting data can also be 
grouped based on similarities between compounds, providing a starting point for 
assigning targets to previously uncharacterized molecules. By combining multiple 
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phenotypic readouts it is more likely that the predicted target pathways will be 
reliable and the number of “hits” should be reduced. 
As various technologies improve, it is becoming more reasonable to apply 
the concepts behind chemical genetic screens in model organisms to human 
cells. One way this has been accomplished is by using RNAi screens to aid in 
target identification (Brummelkamp et al., 2006; Luo et al., 2008). As with gene 
deletion in yeast, depleted proteins important for the drug’s mechanism of action 
should impact the phenotype of this drug, frequently affecting cell survival. There 
are additional limitations, however, of using RNAi instead of a gene deletion. 
These include lack of specificity of the RNAi for its protein and varying 
knockdown efficiencies of RNAi. While redundancy within the RNAi library helps 
discern the effects of specific proteins, varying reductions of protein levels after 
RNAi remains a challenge. 
 
Each of the afore-described techniques has been valuable for the 
identification of some targets, but, as mentioned, they all have limitations. As 
technology advances, some limitations are being overcome.  Depending upon 
the drug, the organisms it is active on, and, of course, its elusive target, the ideal 
strategy varies.  
For many diseases, highly effective drugs require a differential effect in 
disease and normal cells. For example, cancer cells are genetically distinct from 
normal cells and taking advantage of this difference may allow a particular drug 
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to be effective in only the diseased cell with few side effects. Thus it is important 
that as methods for target identification advance, studies of the mechanism of 
action of drugs take place in models that are closest to the treatment context. 
This will likely involve approaches that are sufficiently flexible to be used not only 
in different organisms but also in different cell and tissue types.  
 
Methods to identify drug-binding sites 
The value of the small molecule both as a bioprobe and as a drug can be 
limited by a lack of understanding of its mechanism of inhibition and mode of 
target protein binding. Without these data, it can be difficult to improve potency, 
evaluate specificity, and fully explain cellular phenotypes resulting from drug 
treatment. Furthermore identifying binding sites can lead to information about the 
enzyme’s mechanism that can only be guessed at by kinetic experiments. 
Methods to identify the binding site of a small molecule inhibitor include structural 
studies, computational docking, and photo-crosslinking. 
Structural studies that characterize the interaction between small 
molecules and their protein targets rely on two major techniques: x-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscopy. Both of 
these techniques provide data that can be used to build a representation of the 
drug—target complex at atomic resolution. 
X-ray crystallography studies are the most common means of obtaining 
structural information on proteins in complex with small molecules (Blundell and 
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Patel, 2004). This technique relies on forming crystals of the protein bound to the 
small molecule (or soaking crystals of the apo protein in the small molecule 
inhibitor) and then diffracting x-rays off of the crystal to obtain a map of the 
protein’s structure (Hassell et al., 2007). The resulting data provide a robust and 
highly accurate model of the specific interactions between the small molecule 
and its target protein. However, even for established systems, the rate of failure 
for generating structures of protein—inhibitor complexes can be substantial and 
is highly compound-dependent (Chung, 2007). NMR spectroscopy can be used 
to determine structures of target—ligand complexes for proteins that may not be 
amenable to crystallographic studies (Pellecchia et al., 2008). However, 
macromolecular NMR is generally limited to relatively small proteins. 
Structure-based computational modeling is an increasingly popular 
approach to predict small molecule binding sites on proteins. A variety of 
computational techniques exist, of which the most basic is docking (Mobley and 
Dill, 2009). Docking uses known protein and small molecule structures to explore 
many potential ligand-binding sites. These different possibilities are compared 
based upon likely changes in free energy upon binding. In docking approaches, 
the protein is typically considered to be rigid, which is a limitation of the method 
as binding pockets can be hidden and may only reveal themselves when the 
appropriate ligand is bound (Laskowski et al., 2009).  Furthermore, the accuracy 
of docking methods for identifying protein interaction surfaces are frequently low 
(Wass et al., 2011). Other computational modeling tools have been developed to 
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improve upon the accuracy of docking and allow for more unbiased models to be 
created (Mobley and Dill, 2009). However, these methods frequently rely on 
molecular dynamics simulations and are computationally intensive. 
 Photo-crosslinking of the small molecule to its protein target is a valuable 
technique for studying drug—protein interactions. This technique requires the 
small molecule to be engineered so it contains a light-activated crosslinking 
group (for example, a benzophenone group, diazirene, or azido group). 
Treatment of these groups with light results in highly reactive intermediates that 
will form covalent attachments with nearby amino acids. To identify how the small 
molecule binds to the protein, the complex is digested and each peptide is 
examined by mass spectrometry to determine whether it contains a small 
molecule adjunct (Robinette et al., 2006). This method, like affinity 
chromatography, is limited by the design and synthesis of appropriate small 
molecule analogs. It can also be challenging to identify peptides attached to the 
small molecule in complicated mass spectra. 
In addition to these methods, other biochemical and biophysical strategies 
can be used to study the interactions between a drug and its target. Mutagenesis 
studies are frequently utilized to validate the binding sites suggested by the 
methods described above. Analysis of the location of resistance-conferring 
mutations in a protein’s structure can also predict potential interaction surfaces 
(Luo et al., 2007). Binding sites can also be computationally predicted from 
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protein sequence, conservation, and structural features of related proteins (Wass 
et al., 2011).  
  
Thesis overview 
 The development of new methodological tools to better understand small 
molecule—protein interactions is an essential part of improving the use of 
bioactive compounds both as drugs and as bioprobes. Identifying small molecule 
targets and characterizing the binding site of a small molecule can provide 
unexpected opportunities to improve a compound’s selectivity and potency. While 
there are a number of techniques available for both of these purposes, all have 
limitations. The goal of my thesis research was to develop new ways of studying 
small molecules to expand the chemical biology toolbox. 
The topic of chapter 2 is a method that allows for the identification of small 
molecule targets in human cells by examining drug resistance. I will describe my 
proof-of-concept studies that suggest combining transcriptome sequencing and 
bioinformatics allows for a robust and general way of identifying drug targets. 
In chapter 3 I describe another method, which builds upon photo-
crosslinking studies, to help determine how a small molecule and protein interact. 
I use this technique to investigate the binding of a small molecule inhibitor of an 
essential kinesin protein. 
A general analysis of my thesis and ideas for future experiments are 




Chapter 2: Using transcriptome sequencing to identify 
mechanisms of drug action and resistance 
 
Summary 
 As described in chapter 1, identifying the target(s) of a small molecule 
remains a major challenge in drug development and chemical biology.  Here, I 
discuss an approach that combines next-generation sequencing and 
bioinformatics analyses to identify mutations associated with drug resistance, 
including mutations in the drug’s target.  
In this method, multiple drug resistant clones are isolated from a 
heterogeneous population of human cells.  These resistant clones are analyzed 
by transcriptome sequencing along with the parental population to identify 
mutations unique to the drug-resistant clones. I show that further analysis of 
mutations common to more than one independent clone can lead to a drug’s 
physiological target and indirect resistance mechanisms.   
In proof-of-concept studies, I analyze clones resistant to two cytotoxic anti-
cancer drugs, BI 2536 and bortezomib. In the case of BI 2536 I identify two 
mutations within the drug’s known target, Plk1, that confer resistance to BI 2536 
both in cells and in vitro. For bortezomib, I obtain a list of five genes that are 
mutated in more than one clone, including the drug’s known target, PSMB5. I 
show that the mutations in PSMB5 are sufficient for conferring resistance to 
	  24 
bortezomib in cells. This approach has a number of advantages over other target 
identification methods, particularly that it can establish a genetic proof of the 
target in human cells.  
 
Introduction 
 One of the major problems in developing drugs or chemical probes is the 
difficulty in finding their physiological targets (Burdine and Kodadek, 2004). 
Currently, approaches to analyze how a drug acts fall into two classes. The first 
category includes strategies that rely on model organisms that are amenable to 
genetic manipulations (Chan et al., 2009; Giaever et al., 1999; Ho et al., 2009). 
However, many drugs active in humans are inactive in these model organisms, 
possibly due to multi-drug resistance mechanisms and target divergence 
(Walker, 1982). The second category includes affinity-based methods that are 
used to identify proteins that bind the drug (Ong et al., 2009; Rix and Superti-
Furga, 2009). These approaches are generally effective when the drug is potent 
and the targets are reasonably abundant in vivo. However, establishing that a 
drug-binding protein is the relevant physiological target depends on correlations 
between chemical inhibition in vitro and protein knockdown phenotypes. These 
correlations often prove to be misleading for several reasons, including 
differences between activity inhibition, which can be acute, and the phenotypes 
associated with loss of a protein, which can be indirect or result from cumulative 
effects (Weiss et al., 2007). Currently, we lack an approach that addresses these 
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limitations and can be directly used to discover mechanisms of drug action in 
human cells. 
The gold standard in identifying a drug’s target is achieved when two 
criteria are met. First, it must be shown that resistance to a drug in a 
physiological context occurs through mutations in the candidate target protein. 
Second, in the case of direct targets, these mutations should suppress inhibition 
of the target’s activity by the drug. This standard is met for a few drugs, such as 
Gleevec, for which focused analyses of the expected target led to the 
identification of these mutations (Azam et al., 2003; Gorre et al., 2001). However, 
the large size and complexity of the human genome has limited the unbiased 
analyses of genetic mechanisms conferring drug resistance. Thus, general 
approaches to find drug targets through examining drug resistance in human 
cells are not currently available.  
My colleagues and I sought to develop an approach that could achieve 
gold standard validation of a drug’s target and could be applied to relevant 
human cell types (e.g. cancer cells).   To accomplish this, next-generation 
sequencing and bioinformatics analyses were used to identify mutations in drug 
resistant clones isolated from cultured human cell lines. While several differences 
in the sequences of individual drug-resistant clones are likely, if mutations 
occurred at high frequency in the drug’s direct target, then analyzing mutations 
common to multiple clones might focus the analysis on a handful of potential drug 
targets. When combined with additional biochemical analyses, these data could 
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lead to the gold standard validation of the drug’s physiological target. As a proof 
of concept I analyzed the mechanisms that confer resistance to two drugs, BI 
2536 and bortezomib (Figure 2.1), whose targets are known.  
 
Proof-of-concept studies with BI 2536 
BI 2536 is a dihydropteridinone that is currently in clinical trials and inhibits 
Polo-like kinase 1 (Plk1), a major cell cycle regulator (Lenart et al., 2007). To 
isolate drug-resistant clones I used a human colon cancer cell line, HCT-116, 
which is deficient in mismatch repair and has low expression of multi-drug 
resistant (MDR) pumps (Teraishi et al., 2005).  Therefore, HCT-116 behaves like 
a mutagenized cell line, facilitating the rapid identification of mutations that confer 
drug resistance (Girdler et al., 2008; Glaab and Tindall, 1997). From fifteen BI 
2536-resistant clones (clones were isolated from selections with 10 nM BI 2536, 
LD50: 3.9 ± 2.8 nM), I randomly selected six clones for transcriptome sequencing 
(also called RNA-seq). The LD50s for BI 2536 were 3-9 fold higher in these clones 
than in the parental cell line (Figure 2.2). In parallel, the parental cell line was 
also processed for transcriptome sequencing.  
The sequencing data were analyzed by identifying single nucleotide 
variations and short insertions/deletions (indels) in each clone and only those 
present in coding sequences were further considered. 6-14 single nucleotide 
variations were significantly increased (with a 0.5% false discovery rate) in the BI 



















Figure 2.2 BI 2536 resistant clones were obtained through selection with 
drug. (a) Median lethal dose values (LD50s) were obtained by measuring the 
number of metabolically active cells after treatment with a range of 
concentrations of BI 2536. (b) BI 2536 LD50s calculated for the parental HCT-116 
cells and the six BI 2536-resistant clones processed for transcriptome 





Tables A1-A6; no indels were found). Similar clones were then identified and 
merged into groups using a clustering approach. This clustering analysis 
determined how similar two clones were based on the number of single 
nucleotide variations they had in common. Among the six clones, A, B, and C 
were found to be independent (referred to as groups 1, 2, and 3, respectively), 
while D, E, and F formed a single group (group 4, Figure 2.3a). I further focused 
my analysis on genes that were mutated in more than one independent BI 2536-
resistant group. While there were no genes common to all groups, PLK1 was the 
only gene mutated in more than one group (Figure 2.3b).  
Two distinct mutations in the Plk1 protein were identified, G63S and 
R136G, both of which map to the binding site of BI 2536 in the crystal structure of 
Plk1 (Figure 2.3b, c) (Kothe et al., 2007). To examine whether these mutations 
are sufficient for conferring resistance to BI 2536, I generated stable cell lines 
expressing GFP-tagged full-length Plk1 wild type, G63S, or R136G. Independent 
cell lines were used as secondary mutations were less likely to be common 
between these lines and the parental HCT-116 cells. The R136G mutation 
suppressed BI 2536 toxicity in hTERT-RPE1 cells (Figure 2.4a), and the G63S 
mutation suppressed toxicity both in hTERT-RPE1 (Figure 2.4a) and in HeLa 
cells (Figure 2.4b). These data suggest that Plk1 is the major physiological 
target of BI 2536. Published data show that the R136G mutation has reduced 
sensitivity to BI 2536 in vitro (Scutt et al., 2009). To determine whether the G63S 







Figure 2.3 Bioinformatics analysis of BI 2536-resistant clones. (a) Graph-
based analysis of similarities (0 = low similarity, 2 = high similarity) between BI 
2536-resistant clones allows clones D, E, and F to be grouped together (group 
4). (b) Genes and the coding mutations identified in more than one independent 
BI 2536-resistant group. (c) Amino acids Arg136 and Gly63 in Plk1, both mutated 
in BI 2536-resistant clones, are proximal to the BI 2536 binding site (PDB: 2RKU) 








Figure 2.4 The effects of BI 2536 exposure on human cells expressing Plk1 
wild type and mutant proteins. (a) Proliferation assay showing the effects of BI 
2536 exposure on hTERT-RPE1 cells stably expressing Plk1-GFP wild type (wt), 
Plk1-GFP G63S, or Plk1-GFP R136G. LD50s: 44 ± 5 nM (GFP-Plk1 wt), 83 ± 9 
nM (GFP-Plk1 G63S), 76 ± 8 nM (GFP-Plk1 R136G); n = 6, mean ± sem, p < 
0.01 for both, two-tailed paired t-test.  (b) Proliferation assay showing the effects 
of BI 2536 exposure on HeLa cells stably expressing Plk1-GFP wt and Plk1-GFP 
G63S. LD50s: 1.0 ± 0.2 nM (GFP-Plk1 wt) and 2.7 ± 0.3 nM (GFP-Plk1 G63S); n 






wild type and G63S proteins in insect cells and used these proteins in kinase 
assays (Figure 2.5). While the G63S protein was less active than wild type Plk1 
(~5-fold), it also was substantially resistant to BI 2536 (Figure 2.5b). Therefore, 
these data provide the gold standard proof that Plk1 is the target of BI 2536. 
BI 2536-resistant group 4 (representing clones D, E, and F) did not have a 
mutation in the PLK1 gene, suggesting a different resistance mechanism. Group 
4 clones suppress not only cell growth, but also the characteristic cell division 
phenotype associated with the loss of Plk1 activity. In particular, the reduction in 
bipolar spindles, associated with BI 2536 treatment (Figure 2.6a), is suppressed 
in these clones (Figure 2.6b). This raised the possibility that increased drug 
efflux is a potential resistance mechanism in these clones. An unbiased survey of 
all transcript levels (see Appendix 1), which can be determined from the 
RNAseq data, revealed that ABCB1 (P-glycoprotein, a drug efflux transporter) 
was among the most highly over-expressed mRNAs in group 4 clones (Figure 
2.6c). Consistent with the hypothesis that the intracellular concentration of BI 
2536 was lowered by drug efflux, group 4 clones had reduced sensitivity to the 
chemically-unrelated drug taxol, a compound known to be transported by the 
ABCB1 pump (Yusuf et al., 2003) (Figure 2.6d). While further experiments are 
needed to establish if BI 2536 resistance in group 4 clones is via ABCB1 drug 
efflux, my data suggest that this approach can lead to testable hypotheses for 







Figure 2.5 Kinase assay showing response of Plk1 wild type and Plk1 G63S 
to BI 2536 in vitro. (a) Recombinant full-length Plk1 wild type (wt) and Plk1 
G63S can phosphorylate casein (which runs as two bands on a 4-20% gel), as 
analyzed be transfer of γ-32P. BI 2536 inhibits this activity in a dose dependent 
manner for both proteins.  (b) Quantification of phosphorylated casein bands 
were quantified, with activity reported as a percentage of the control (5% DMSO).  
IC50s: 6.2 ± 1.3 nM (Plk1 wt), 128 ± 3 nM (Plk1 G63S); n = 3, mean ± sem.  
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Figure 2.6 Analysis of the mechanism of resistance of group 4 clones. (a-b) 
Analysis of microtubule (green) and chromosome (blue) organization in dividing 
cells treated with BI 2536 (50 nM). Normal bipolar spindles were observed in only 
11 ± 3% of HCT-116 cells. A typical monopolar spindle observed in these cells is 
shown (a). In comparison, 46 ± 4% of the spindles in the drug-resistant clone E 
were bipolar, as shown (b). Scale bar, 2 μm. (c) Expression levels of the ABCB1 
mRNA in the parental HCT-116 cells and the six BI 2536-resistant clones. Levels 
are measured as the number of reads per kilobase, per million reads (RPKM). (d) 
Proliferation assay showing the effect of 20 nM taxol on HCT-116 parental cells 




Proof-of-concept studies with bortezomib 
I next examined if this approach could be applied to another drug. 
Bortezomib (Figure 2.1b) is a boronic acid dipeptide that inhibits the proteasome 
through its subunit PSMB5 and is used clinically to treat multiple myeloma and 
mantle cell lymphoma (Chen et al., 2011). Nineteen clones were isolated from 
HCT-116 cells grown in the presence of bortezomib (8 – 12 nM, LD50: 6.3 ± 0.9 
nM). Five clones, with reduced bortezomib sensitivity (LD50s 2.4 – 6.5 fold higher, 
Figure 2.7), were processed for transcriptome sequencing. 15 – 28 single 
nucleotide variations were identified from each clone (Appendix 1, Tables A7-
A11). Using clustering analysis (Figure 2.8a) clones A, B, C, and D were 
grouped together (group 1) and clone E was found to be independent (group 2). 
Five genes were mutated in both bortezomib-resistant groups (Figure 2.8b). The 
only gene with two distinct mutations (M104V and A108T) was PSMB5, the 
known target of bortezomib. The existence of two distinct resistance mutations 
would make PSMB5 the highest priority gene for further analysis if the target of 
bortezomib was not already known. However, the remaining four genes would 
also need to be examined as potential targets.  
I found that expression of GFP-tagged PSMB5, carrying either the M104V 
or A108T mutations, suppressed bortezomib sensitivity in an independent cell 
line (hTERT-RPE1, Figure 2.9a). This is consistent with previous reports that 
A108T confers bortezomib-resistance (Lu et al., 2008; Oerlemans et al., 2008). 







Figure 2.7 Bortezomib-resistant clones were obtained through selection 
with drug. (a) Median lethal dose (LD50s) were obtained by measuring the 
number of metabolically active cells after treatment with a range of 
concentrations of bortezomib. (b) Bortezomib LD50s calculated for the parental 
HCT-116 cells and the five bortezomib-resistant clones processed for 











Figure 2.8 Bioinformatics analysis of bortezomib-resistant clones. (a) 
Graph-based analysis of similarities (0 = low similarity, 2 = high similarity) 
between bortezomib-resistant clones allows clones A, B, C, and D to be grouped 
together (group 1). (b) Genes and the coding mutations identified in more than 








Figure 2.9 Characterization of PSMB5 mutations found in bortezomib-
resistant clones. (a) Proliferation assay showing the effect of treatment with 
bortezomib on hTERT-RPE1 cells that are stably expressing GFP-PSMB5 wild 
type (wt), GFP-PSMB5 M104V, or GFP-PSMB5 A108T, in addition to the 
endogenous wild type gene. LD50s: 5.55 ± 0.09 nM (GFP-PSMB5 wt), 28.7 ± 2.8 
nM (GFP-PSMB5 M104V), 19.2 ± 2.8 nM (GFP-PSMB5 A108T); n = 3, mean ± 
sem, both p < 0.05, two-tailed paired t-test. (b) Amino acids Met104 and Ala108 
in Pre2 (yeast homolog of PSMB5), a subunit of the 20S proteasome, are 







hypothesize that they directly suppress drug interactions (Figure 2.9b) (Groll et 
al., 2006). While additional biochemical tests are needed to examine this further, 
my data indicate that the method described here can efficiently lead to resistance 
mechanisms that include a drug’s direct target.  
 
Directed analysis of frequency of mutations in target 
My analysis thus far indicates that for this approach to be applicable, 
resistance via mutations in a drug’s direct target must occur at high frequency in 
drug-resistant clones.  To examine how frequently this occurs, I examined the 
sequence of the PLK1 gene in each of the nine BI 2536-resistant clones that had 
not already been processed by RNA-seq.  The frequency at which the PLK1 
gene was mutated was ~45% (4 of 9 clones, Table 2.1).  
I next analyzed two kinesin-5 inhibitors, S-Trityl-L-cysteine (STLC), which 
is known to be selective (Skoufias et al., 2006), and 4-(2-(1-phenylcyclopropyl) 
thiazol-4-yl)pyridine (PCTP), which has been shown to inhibit other related motor 
proteins in vitro (Rickert et al., 2008). I obtained resistant clones for these 
inhibitors (1 μM STLC in selections, LD50: 0.63 ± .06 μM; 8 – 12 μM PCTP in 
selections, LD50: 2.2 ± 0.1 μM). Kinesin-5 mutations were found in ~30% of the 
STLC-resistant clones (4 of 14 clones, Figure 2.10) and in ~15% of PCTP 
resistant clones (3 of 22 clones, Figure 2.11). These data indicate that 












Figure 2.10 Characterization of STLC-resistant clones. (a) Chemical structure 
of the kinesin-5 inhibitor S-trityl-(L)-cysteine (STLC). (b) Fourteen clones were 
isolated from selections with 1 μM STLC (LD50: 0.63 ± 0.06 μM). RT-PCR and 




Figure 2.11 Characterization of PCTP-resistant clones. (a) Chemical structure 
of the kinesin-5 inhibitor 4-(2-(1-phenylcyclopropyl)thiazol-4-yl)pyridine (PCTP). 
(b) Twenty-two clones were isolated from selections with 8 – 12 μM PCTP (LD50: 
2.2 ± 0.1 μM). RT-PCR and Sanger sequencing identified mutations in the 
kinesin-5 RNA of 3/22 clones.  
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major physiological target (as is the case for STLC, BI 2536 and bortezomib). 
When a drug has multiple targets (for example, PCTP) it is likely that resistance 
in a single target will be less frequent and thus this approach may be limited as a 
greater number of clones have to be sequenced in order to identify genes with 
mutations in more than one clone. 
 
Selections with additional compounds 
While selecting for resistant clones to BI 2536, bortezomib, STLC, and 
PCTP I also attempted to select for resistance to additional compounds. These 
compounds include two molecules with known targets, the microtubule inhibitor 
taxol (Horwitz, 1994) and the Aurora kinase inhibitor hesperadin (Hauf et al., 
2003) (Figure 2.12a and b). I examined these compounds at the same time as 
bortezomib with the aim of characterizing the generality of my approach. 
Additionally, I selected for resistant clones with compounds that I hoped would 
allow me to use my method to identify novel targets. These compounds include 
ARQ-197 (Figure 2.12c), which is published as a c-Met inhibitor (Munshi et al., 
2010), but may have additional targets and two cytotoxic compounds without 
clearly defined targets, BE-54017 and Cladoniamide A (Figure 2.12d, e). Each of 
these drugs failed at some point during the resistance selection process and 
likely did so for a variety of reasons. My results with these inhibitors suggest 








Figure 2.12 Structures of small molecules taxol (a), hesperadin (b), ARQ-





Selections with the Aurora inhibitor hesperadin were conducted at 
compound concentrations of 0.1 – 3 μM. At 3 μM all cells died and the plates 
were completely clear; this is a common feature of especially high drug 
concentrations and was also observed during selections with bortezomib and 
STLC. At concentrations between 400 nM and 2 μM, a few cells remained on 
each selection plate, with more cells remaining on plates with lower 
concentrations of hesperadin. These cells did not divide and no colonies formed. 
At very low concentrations of hesperadin (100 – 300 nM) much of the plate was 
covered with cells and it was impossible to pick individual colonies.  The 
observations with the high (3 μM) and low (100 – 300 nM) concentrations of 
hesperadin are common and not surprising. However, I have not previously 
observed plates that contain only non-dividing single cells, as were present in the 
mid-concentration hesperadin selections. The presence of these individual cells 
that precluded growth of resistance colonies is surprising as similar selections 
have been successful with another Aurora kinase inhibitor, ZM447439 (Girdler et 
al., 2008). This difference between the two Aurora kinase inhibitors may be due 
to variations in the mechanism of action of the two drugs. These findings suggest 
that for drugs that elicit certain cell states (for example, senescence, not cell 
death) my approach may be unsuccessful. Fortunately, this should be able to be 
determined at an early stage of the analysis (during resistance selection).  
Selections with taxol (2.5 – 7.5 nM) resulted in the isolation of twenty-eight 
taxol-resistant clones. Before further analysis, I randomly selected clones for 
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testing and found they were 2 – 20-fold less sensitive to taxol than the parental 
cells (Figure 2.13a). Interestingly, all of the clones tested were also, to a similar 
extent, less sensitive to BI 2536 (Figure 2.13b). This suggests that these clones 
have multi-drug resistance. This finding is not surprising as the most common 
clinical resistance mechanism for taxol is also multi-drug resistance, specifically 
up-regulation of the drug pump ABCB1 (Horwitz et al., 1993). As all clones tested 
displayed this same multi-drug resistance phenotype, I hypothesize that some 
genes, such as those that encode highly conserved and essential proteins like 
tubulin, are not amenable to spontaneous mutation, as required for my approach. 
For these target proteins, my method will not likely be effective.  
Selections with ARQ-197 (750 – 850 nM) resulted in thirty-six clones. 
Upon further testing, all of the tested clones had LD50 values that were 1.5-fold or 
less the value of the parental LD50 (Figure 2.14). Furthermore, as there was such 
a small change in drug sensitivity over the parental cells, it was unclear whether 
these clones had altered sensitivity to taxol (a 1.5-fold change in taxol’s LD50 
could not be robustly identified). ARQ-197, which is published as a c-Met inhibitor 
(Munshi et al., 2010), elicits cellular signaling phenotypes that are not fully 
consistent with c-Met inhibition (personal communication, Pasi A. Jänne). 
Furthermore, the lack of strongly resistant ARQ-197 clones suggests that the 
compound may have multiple targets. To further characterize the potential 
target(s) of ARQ-197 I examined its phenotype in HCT-116 cells by microscopy. I 









Figure 2.13 Taxol-resistant clones were obtained through selection with 
drug. Median lethal dose values (LD50s) were obtained by measuring the number 
of metabolically active cells after treatment with a range of concentrations of taxol 












Figure 2.14 ARQ-197-resistant clones were obtained through selection with 
drug. Median lethal dose values (LD50s) were obtained by measuring the number 
of metabolically active cells after treatment with a range of concentrations of 





phenotype that closely mimics cell treatment with the microtubule poison 
nocodazole (Figure 2.15). While I have not been able to show an effect of  
ARQ-197 on microtubules in vitro, my cellular data support the idea that ARQ-
197 has a target other than c-Met.  
The compounds BE-54017 and Cladoniamide A were brought to my 
attention by Fang-Yuan Chang in Sean Brady’s laboratory at Rockefeller 
University, who is interested in their biosynthesis. As the mechanisms of action of 
these cytotoxic compounds are unknown, I hoped that my method might help to 
elucidate their targets. Selections with BE-54017 (200 – 400 ng/ml) and 
Cladoniamide A (150 – 200 ng/ml) allowed for several colonies to form. However, 
the obtained clones were not able to survive multiple passages in the appropriate 
concentration of drug. As no clones remained, these compounds were not further 
pursued. Together my data suggest that this approach should be successful for 
drugs that have single easily-mutated targets, but that my method will be less 
successful when a drug has multiple targets. When the method will not be 
successful, it is likely that there will be an indication of this during an early stage 
(i.e. before transcriptome sequencing).  
 
Discussion 
Along with my collaborators, I have developed a method to identify the 
targets of drugs in human cells by examining resistance mechanisms. This 





Figure 2.15 Effect of ARQ-197 on HCT-116 cells. Analysis of microtubule 
(green) and chromosome (blue) organization in interphase (a) and dividing cells 
(b) treated with DMSO, nocodazole (150nM), or ARQ-197 (500 nM) for four 
hours. (c) The percentage of cells that are mitotic after each treatment is plotted 






Figure 2.16 Schematic highlighting the key steps of the approach. Selecting 
and expanding drug-resistant clones from a heterogeneous parental population.  
Massively parallel sequencing of mRNA from multiple drug-resistant clones and 
parental (untreated) cells. Bioinformatics analyses to identify genes that are 
mutated with high frequency. A subset of sequencing reads for a BI 2536-
resistant clone (clone A) and the HCT-116 parental cells are shown. The ~50% 




heterogeneous human cells are treated with a drug at concentrations that kill 
most cells. Then, multiple drug resistant clones are selected and expanded. 
Based on my analysis with BI 2536, clones with multi-drug resistance can be 
excluded by testing for reduced sensitivity to unrelated compounds. The 
remaining clones are processed for transcriptome sequencing, along with the 
parental (untreated) cell population. Mutations in coding sequences of the 
resistant clones, not observed in the parental cell population, are identified. 
Mutations that arise in more than one independent clone suggest resistance 
mechanisms. Biochemical and cell biological assays can then be used to 
examine which of these resistance mechanisms represent the drug’s direct target 
and which are indirect resistance mechanisms.  
My strategy has some advantages over other approaches to identify a 
drug’s target. First, unlike many other target identification approaches, this 
method does not rely on chemical modifications of the drug of interest. This can 
be important when small changes in a drug’s chemical composition can alter its 
mechanism of action (Wood et al., 2010). Second, my approach can be applied 
to any cells that can be grown in culture, enabling cell-type specific analyses, 
which would be particularly useful if a drug is toxic in specific tissues. While this 
approach is currently limited to analyzing cytotoxic drugs, in principle it should be 
possible to extend its use to non-toxic drugs. Furthermore, while my approach 
focuses only on discovering single nucleotide variations and insertions/deletions 
and thus does not report on all potential mechanisms of resistance, these 
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limitations can be addressed by combining the approach with other genomic 
methods.  
In summary, this combined experimental and computational approach has 
the potential to reveal the physiological on-targets of a drug in disease cells, 
unintended off-targets in healthy cells, and can reveal cellular mechanisms of 
drug resistance. These findings can impact chemical modifications of drugs to 
improve efficacy and limit toxicity. When unanticipated drug targets are found 




Chapter 3: Examining the mechanism of action of a kinesin 




Once a small molecule’s target is identified, a remaining challenge is 
characterizing the chemical inhibitor’s binding site within its protein target. This is 
especially difficult if the target—inhibitor interaction requires multi-protein 
mixtures and high-resolution structural studies are not straightforward. Building 
upon previous research involving photo-crosslinking and incorporation of 
mixtures of stable isotopes, I have helped to develop a method, Stable Isotope 
Labeled Inhibitors for Crosslinking (SILIC), for mapping a small molecule 
inhibitor’s binding site in its target protein. In SILIC, structure-activity relationship 
data is used to design inhibitor analogs that incorporate a photo-crosslinking 
group along with either natural or heavy isotopes.  An equimolar mixture of these 
inhibitor analogs is crosslinked to the target protein to yield a robust signature for 
identifying inhibitor-modified peptide fragments in complex mass spectrometry 
data. As a proof of concept, I applied this approach to an ATP-competitive 
inhibitor (called 4-(2-(1-phenylcyclopropyl)thiazol-4-yl)pyridine (PCTP)) of 
kinesin-5, a widely conserved motor protein required for cell division and an anti-
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cancer drug target. This crosslinking analysis, along with mutagenesis studies, 
suggests that the inhibitor binds at an allosteric site in the motor protein.  
 
Introduction 
Photo-crosslinking of small molecules to proteins has been used to trap 
drug—target protein interactions in complex protein mixtures (Chen et al., 2002; 
Seiffert et al., 2000; Shorr et al., 1982). Identifying drug targets and mapping drug 
binding sites after photo-crosslinking typically relies on systematic mass 
spectrometry based analyses of digested protein fragments to identify those with 
a small molecule adduct (Al-Mawsawi et al., 2006; Wood et al., 2010). While 
there are examples of the successful use of this approach, the general 
applicability of the method has been limited as crosslinking is often sub-
stoichiometric (Hermanson, 2008), and the different possible inhibitor—peptide 
adducts can be difficult to detect in complex mass spectra. One strategy to 
address this involves generating inhibitor analogs with an affinity tag for capturing 
the inhibitor—peptide adducts (Salisbury and Cravatt, 2007). In many cases, 
however, the inhibitor’s dual modifications, for photo-crosslinking and affinity-
capture, can alter the compound’s mechanism of action.  
As an alternative approach to identify inhibitor—protein adducts within 
complex mass spectra, inhibitor analogs can be generated such that they carry a 
unique isotope pattern (Kelleher et al., 1997; Weerapana et al., 2010). The 
incorporation of natural and heavy stable isotopes into a benzophenone photo-
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crosslinker moiety appended to the inhibitor of interest has been shown to aid the 
identification of its target in a proof-of-concept study (Lamos et al., 2006). 
However, the method is not likely to be useful for mapping an inhibitor’s binding 
site. This is, in large part, due to the crosslinking group being incorporated via a 
linker, so that it is a significant distance from the functional groups that are likely 
to make key contacts with the target’s binding site. 
Building on these studies, my colleagues and I have developed a method, 
which we call Stable Isotope Labeled Inhibitors for Crosslinking (SILIC), for 
mapping small molecule—protein binding sites. In the first step of this approach a 
photo-crosslinking group is incorporated into the inhibitor of interest (Figure 3.1), 
guided by available structure-activity relationship (SAR) data. Importantly, the 
photo-crosslinking group is appended at a site that does not change the 
inhibitor’s mechanism of action, but is in the closest proximity possible to the 
inhibitor’s activity-conferring functionality, so as to increase the probability that 
crosslinks are at, or near, the protein’s inhibitor-binding pocket. Natural and 
heavy isotope containing inhibitor analogs, which have a mass difference of a 
few daltons but otherwise identical physical properties, are then generated. The 
multi-protein complex to be analyzed is then incubated with a 1:1 mixture of 
natural and heavy inhibitor. After photo-crosslinking and protein digestion, the 
resulting mixture of peptide fragments is separated by HPLC and analyzed using 
high-resolution mass spectrometry. The resulting mass spectra can be 








Figure 3.1 Schematic for SILIC. Inhibitors, with a photo-crosslinking substituent 
and natural (N) or heavy (H) isotopes, are mixed with a complex of proteins, 
including the target (green). After UV-crosslinking, protein digestion, and LC-MS 
one obtains complex mass spectra that can be filtered based upon a ‘signature’ 





of low abundance due to sub-stoichiometric labeling. The peptide-inhibitor adduct 
is identified when a pair of peptides that co-elute in the LC have the expected 
mass difference and essentially equal signal intensity. Finally, guided by these 
data, site-directed mutagenesis experiments can be designed to further examine 
the inhibitor-binding sites identified by SILIC. 
 
Mechanism of action of PCTP 
As a proof of concept, I examined the small molecule (4-(2-(1-
phenylcyclopropyl)thiazol-4-yl)pyridine (PCTP, Figure 2.11a), an inhibitor of 
kinesin-5 (Rickert et al., 2008). Kinesins, which comprise a family of over forty 
proteins, are motor proteins that move cargo along microtubules, polymers of the 
cytoskeletal protein tubulin (Miki et al., 2005; Vale and Milligan, 2000). The 
kinesin-5 family is required for the assembly of the microtubule-based apparatus 
necessary for cell division, which is called the spindle (Sharp et al., 2000). 
Inhibitors of kinesin-5 have provided valuable insight into mechanisms of cell 
division and have entered clinical trials as anti-cancer drugs (Duhl and Renhowe, 
2005; Mayer et al., 1999). Kinesin-5 inhibitors that are in clinical trials, and have 
been used for cytological experiments, bind an allosteric site not conserved in 
other kinesins (Maliga et al., 2002; Yan et al., 2004). These inhibitors are not 
competitive with respect to ATP (Cochran and Gilbert, 2005). Recently, ATP-
competitive inhibitors of kinesin-5 have been reported, including PCTP (Luo et 
al., 2007; Rickert et al., 2008). Of these, PCTP stood out as it has been shown to 
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inhibit other kinesin proteins (Rickert et al., 2008). Since the ATP-binding site is 
the most conserved feature in kinesins, I was interested in using PCTP as a 
possible starting point for developing new inhibitors of other kinesins.  However, 
the binding site of PCTP in kinesin-5 or any of the kinesins it inhibits is not 
known. Both other research groups and I have unsuccessfully attempted to 
obtain a crystal structure of the PCTP-kinesin-5 complex (Rickert et al., 2008) 
(see Appendix 2).  
To map the binding site of PCTP, I first analyzed its mechanism of action. 
Interestingly, PCTP inhibits steady state ATP hydrolysis by kinesin-5’s motor 
domain (residues 1-368, expressed in bacteria) 25-times more potently when 
microtubules, the motor protein’s tracks, are present in the reaction (IC50: PCTP 
+ microtubules + kinesin-5 = 1.2 ± 0.3 μM; PCTP + kinesin-5 = 30 ± 7 μM; 
Figure 3.2a). I next examined inhibition of kinesin-5 driven microtubule gliding. 
These assays require protein constructs that are larger than those consisting of 
the monomeric ATPase domain. I found that full-length homotetrameric kinesin-5 
(from Xenopus laevis, expressed in insect cells) drives microtubule gliding at 19.6 
± 4.5 nm/s (1 mM MgATP). Remarkably, even at 50 nM of PCTP, the motor 
activity of kinesin-5 was completely inhibited (Figure 3.2b). As this concentration 
of PCTP is much lower than its IC50, this finding suggests that tightly bound motor 
protein-microtubule complexes are formed in the presence of PCTP and these 
complexes act as brakes against other active motor protein molecules to stop 






Figure 3.2 PCTP inhibition of kinesin-5 is affected by microtubules. (a) 
Representative curve from a steady-state ATP hydrolysis assay showing the 
response of kinesin-5 to PCTP, in the presence and absence of microtubules. 
IC50s: 1.2 µM ± 0.3 (kinesin-5 + microtubules), 30 µM ± 7 (kinesin-5, 
nomicrotubules). IC50 values are averages ± s.d. (n = 3).  (b) In the presence of 
MgATP (1 mM) and DMSO, homotetrameric kinesin-5 drives microtubule gliding 
at an average rate of 19.6 ± 4.5 nm/s (left panel, n > 25). PCTP (50 nM) inhibits 





as rigor, is seen when kinesin proteins are inhibited by a non-hydrolyzable ATP 
analog (Vale et al., 1985). Experiments by Mitchison and colleagues using 
microtubule-pelleting assays confirm my findings that PCTP induces rigor (Groen 
et al., 2008). Together, these ATPase and microtubule gliding assay data 
suggest that the binding mode of PCTP to kinesin-5 should be examined in the 
presence of microtubules and may help explain why I had difficulty obtaining a 
crystal structure of the kinesin motor domain with PCTP in the absence of 
microtubules. Thus, analyzing the PCTP-kinesin-5 interaction in the presence of 
microtubules provides an interesting case for developing and applying the SILIC 
approach. 
 
Examination of PCTP binding with SILIC 
Guided by available SAR data for PCTP (Rickert et al., 2008), a colleague, 
Sudhir Kashyap, designed and synthesized analogs of PCTP, which contain an 
azide substituent on the phenyl ring as a photoreactive group and have natural 
(hydrogen, H; compound 1) and heavy (deuterium, D; compound 2) isotopes 
(Figure 3.3a). Synthesis of compound 1 was based on the published procedure 
for PCTP, but started with 4-bromophenyl-acetonitrile to position the aryl azide 
group (Rickert et al., 2008). To incorporate deuterium atoms that generate a 4 Da 
mass difference compared with 1, toluene-d8 was used as a starting material to 
synthesize the substituted phenyl ring moiety in 2. Notably, the introduction of the 







Figure 3.3 SILIC analogs of PCTP. (a) Chemical structure of PCTP and the 
natural and heavy crosslinkable analogs generated for SILIC. (b) Potency of 
compounds 1 and 2 compared with PCTP in inhibiting kinesin-5 activity, as 
examined using a steady-state microtubule-stimulated ATP hydrolysis assay. 
IC50s: 1.2 µM ± 0.3 (PCTP), 1.2 µM ± 0.4 (compound 1), 1.0 µM ± 0.4 (compound 




expected, the natural and heavy analogs have similar activities against kinesin-5 
(Figure 3.3b, IC50: 1 = 1.2 ± .4 μM; 2 = 1.0 ± .4 μM).  
To conduct crosslinking, a 1:1 mixture of 1 and 2 (3 mM each) was 
incubated with kinesin-5 motor domain and microtubules. After UV irradiation at 
254 nm for 30 min, the reaction mixture was resolved by SDS-PAGE. Following 
in-gel digestion, the peptide mixture was separated and analyzed by LC-MS/MS 
by my colleague Xiang Li. Computer-based analysis with the software MaxQuant 
(Cox and Mann, 2008) was used to efficiently detect peaks with a mass 
difference of 4 Da that eluted at the same time from the LC column.  Manual 
analysis of potential peaks was also conducted. In independent experiments (n = 
3), a single peptide was identified with equal intensity peaks corresponding to the 
expected mass of the peptide plus the mass of 1 and 2 (Figure 3.4a). This 
peptide is likely to be the major inhibitor—peptide adduct. Further analysis by 
MS/MS identified this peptide as a fragment corresponding to Ser120 – Arg138 of 
kinesin-5 and the crosslinking site of the inhibitors is very likely at one of three 
amino acid residues (Tyr125, Thr126, or Trp127) (Figure 3.4b).  
I next examined whether excess PCTP can suppress the crosslinking of 1 
(or 2) to kinesin-5. For this experiment, I crosslinked kinesin-5 with 1 (3 μM) in 
the presence of excess PCTP (45 μM) and, in parallel, crosslinked kinesin-5 with 
2 (3 μM) alone. These samples were then mixed and processed for mass 
spectrometry analysis. This protocol provided a quantitative readout of the 








Figure 3.4 Crosslinking of PCTP analogs to kinesin-5. (a) A representative 
mass spectrum of the ‘signature’ peaks that denote peptide fragments of kinesin-
5 crosslinked by equimolar 1 (pink circles) and 2 (blue squares) in the presence 
of microtubules. Cartoon shows kinesin-5 (green) and microtubules (red) with 
crosslinking compounds. (b) The MS/MS spectrum and summary of fragmented 




suppressed. As shown in Figure 3.5, PCTP competes with 1, suggesting that 
PCTP also binds at a site proximal to residues Tyr125, Thr126, and Trp127. 
In the three-dimensional structure of the kinesin-5 motor domain, residues 
Y125, T126, and W127 map to a portion of loop-5 (Figure 3.6, PDB: 2WOG) 
(Kaan et al., 2010). This loop is part of an allosteric binding site for several other 
kinesin-5 inhibitors (Kaan et al., 2010; Yan et al., 2004), including S-Trityl-L-
cyteine (STLC, IC50 = 1 μM, steady-state ATPase assay without microtubules 
(DeBonis et al., 2004)). As these inhibitors bind this pocket in the absence of 
microtubules, I examined if PCTP did the same. To test this, I repeated the 
crosslinking and competition experiments in the absence of microtubules and 
found the same single crosslinking site (Figure 3.7). Furthermore, I found that 
addition of excess STLC (50 mM) prevented crosslinking of 1 (5 mM) to kinesin-
5, relative to the reference sample (kinesin-5 crosslinked to 2, Figure 3.8). 
Together, these data suggest that PCTP, like STLC, binds in the allosteric loop-5 
site. 
 
Site-directed mutagenesis to characterize PCTP—kinesin-5 interaction 
I next used site-directed mutagenesis to analyze whether inhibition of 
kinesin-5 by PCTP was sensitive to changes in the allosteric pocket. A leucine-
214 to alanine (L214A) mutation, in this allosteric binding site of kinesin-5 
(Figure 3.6), is known to suppress STLC inhibition (Brier et al., 2006). Using the 








Figure 3.5 PCTP competes with 1 for kinesin-5 binding. When 1 (3 μM) is 
crosslinked in the presence of PCTP (45 μM), there is near complete loss of 












Figure 3.6 The loop-5 region of the kinesin-5 motor domain. The kinesin-5 
motor domain (green, PDB: 2WOG) (Kaan et al., 2010) in complex with ADP 
(orange) and STLC (blue). The crosslinked residues Y125, T126, and W127 are 









Figure 3.7 Mass spectrum of peptide—inhibitor adduct after crosslinking of 
kinesin-5 with 1 and 2 in the absence of microtubules. The ‘signature’ peaks, 
with the expected isotopic distribution and mass differences indicate crosslinking 








Figure 3.8 STLC competes with 1 for kinesin-5 binding. When 1 (5 μM) is 
crosslinked in the presence of STLC (50 μM), there is near complete loss of 




that this mutation led to a ten-fold increase in the potency of PCTP (Figure 3.9). 
Importantly, crosslinking of 1 and 2 to kinesin-5, which had the L214A mutation, 
resulted in identification of the same binding site (Figure 3.10). In addition, I find 
PCTP is an ATP-competitive inhibitor of the kinesin-5 L214A mutant (Figure 
3.11), indicating that the mode of inhibition is not altered by this mutation. These 
data provide further evidence supporting the model that PCTP binds to the loop-5 
site. 
In chapter 2, I described selections for clones resistant to PCTP. These 
clones contained two distinct mutations in kinesin-5 that are correlated with 
resistance to PCTP in cells (Figure 2.11, Figure 3.12). These mutations, Y104H 
and S269N, do not map to the loop-5 region of kinesin-5 but do map together in 
the three-dimensional structure of kinesin-5 (Figure 3.13, PDB: 2WOG) (Kaan et 
al., 2010). I decided to examine whether these mutations confer PCTP resistance 
to kinesin-5 in vitro. I found that both mutations confer resistance to PCTP in a 
steady-state microtubule-stimulated ATPase assay with the motor domain of 
kinesin-5 (Figure 3.14a). Interestingly, in the absence of microtubules, these 
mutations do not confer resistance to PCTP (Figure 3.14b). Kinesin-5 S269N is 
actually more sensitive to PCTP than the wild type protein in the absence of 
microtubules.  To determine whether kinesin-5 S269N may significantly alter the 
structure of kinesin-5 I conducted crystallography studies (see Appendix 2).  
During the mass spectrometry peak finding analysis, I carefully examined 






Figure 3.9 Effect of PCTP on kinesin-5 L214A. (a) Representative curve from a 
microtubule-stimulated steady-state ATP hydrolysis assay showing the response 
of kinesin-5 wild type (wt) and L214A to PCTP. IC50s: 1.2 µM ± 0.3 (kinesin-5 wt), 
110 nM ± 60 (kinesin-5 L214A). (b) Representative curve from a steady-state 
ATP hydrolysis assay in the absence of microtubules showing the response of 
kinesin-5 wild type (wt) and L214A to PCTP. IC50s: 30 µM ± 7 (kinesin-5 wt), 2.4 











Figure 3.10 Crosslinking of PCTP analogs to kinesin-5 L214A. Mass 
spectrum of peptide-inhibitor adduct after crosslinking of kinesin-5 L214A with 1 
and 2 (no microtubules). The ‘signature’ peaks, with the expected isotopic 









Figure 3.11 Lineweaver-Burk plots of kinesin-5 wild type (a) and L214A 
mutant (b). Plots were made using microtubule-stimulated ATPase activity at 25 
µM, 50 µM, 100 µM, 200 µM, 500 µM, and 1 mM ATP. Individual linear 
regressions were calculated for each inhibitor concentration. Data values are 







Figure 3.12 PCTP-resistant clones were obtained through selection with 
drug. (a) Median lethal dose values (LD50s) were obtained by measuring the 
number of metabolically active cells after treatment with a range of 
concentrations of PCTP. (b) HCT-116 parental cells and clones 11 and 12 were 
treated with PCTP for five hours before methanol fixation. Fixed cells were 
stained for tubulin and DNA before they were counted under the microscope. The 








Figure 3.13 Residues Y104 and S269 in the motor domain of kinesin-5. The 
kinesin-5 ATPase domain (green, PDB: 2WOG) (Kaan et al., 2010) in complex 







Figure 3.14 Effect of PCTP on kinesin-5 Y104H and S269N. (a) Microtubule-
stimulated steady-state ATP hydrolysis assay (plotted values are mean ± sem) 
showing the response of kinesin-5 wild type (wt), Y104H, and S269N to PCTP. 
IC50s: 1.2 µM ± 0.3 (kinesin-5 wt), 14 µM ± 2 (kinesin-5 Y104H), 32 µM ± 3 
(kinesin-5 S269N). (b) Steady-state ATP hydrolysis assay in the absence of 
microtubules (plotted values are mean ± sem) showing the response of kinesin-5 
wild type (wt), Y104H, and S269N to PCTP. IC50s: 30 µM ± 7 (kinesin-5 wt), 28 
µM ± 2 (kinesin-5 Y104H), and 9.3 µM ± 3 (kinesin-5 S269N). Values are 






however, I never saw any indication of crosslinking. Thus, my interpretation is 
that the kinesin-5 site represented by Y104 and S269 is an allosteric regulatory 
site that moves upon microtubule binding, while the loop-5 region is the binding 
site of PCTP. Thus my model is that PCTP binds at or near the site bound by 
other kinesin-5 inhibitors that are not ATP-competitive.  
 
Discussion 
In summary, I’ve demonstrated that SILIC can be used to map the binding 
site of an inhibitor to its target. This approach should be effective in analyzing 
inhibitor-target interactions, particularly when structural studies are intractable. A 
potential limitation of the approach is that the incorporation of a photo-
crosslinking moiety, such as an aryl azide, may not always be feasible. However, 
aryl groups appear at high frequency in bioactive small molecules. In these 
cases, SAR studies could allow the inclusion of an azide moiety such that it does 
not alter the inhibitor’s mechanism of action and yet is proximal to the target’s 
binding site residues. In the future this approach may be extended to more 
complex cellular contexts to examine whether cellular physiology alters the mode 





Chapter 4: Conclusions and Discussion 
 
In the preceding chapters I have presented two methods that I hope will 
benefit the study of small molecule inhibitors and the proteins to which they bind. 
In this section of my thesis I will describe in greater detail some of my findings 
and their implications. For chapter 2 I will present ideas for further improving and 
expanding the scope of my method for target identification. I will also analyze my 
results regarding kinesin-5 and PCTP that were reported in chapter 3. 
 
My approach to target identification 
In chapter 2, I described an approach that combines next-generation 
sequencing technology with bioinformatics analyses in order to examine 
pathways and proteins involved in drug resistance and action. My studies with 
the drugs BI 2536 and bortezomib indicate that, by analyzing drug-resistant 
clones through transcriptome sequencing and bioinformatics, a short list of 
potential drug targets can be obtained. Biochemical and cytological studies are 
then used to validate which of these proteins are direct targets and which 
represent indirect mechanisms of action. 
While others have previously isolated resistant clones from human cells 
and analyzed resistance mutations in a targeted fashion (Girdler et al., 2008), 
before I began this study it was not clear whether resistance mutations could be 
	  79 
identified in an unbiased manner in human cells.  My approach takes advantage 
of next-generation DNA sequencing methods and robust bioinformatic analyses 
to overcome the large size and complexity of the human genome and the genetic 
heterogeneity associated with many human cell lines, particularly those which 
can be grown in culture. By isolating multiple drug resistant clones and grouping 
those that are closely related, it is possible to obtain a short list of genes which 
represent potential drug targets.  
Importantly, the use of RNA-seq provides information on single nucleotide 
variations, insertions/deletions, and mRNA transcript levels (Wang et al., 2009).  I 
have shown that both the mutational analysis (which includes single nucleotide 
variations and insertions/deletions) and the transcript level analysis can be 
crucial to the discovery of drug resistance mechanisms. A limitation of the 
method, though, is that only genes with sufficient sequencing coverage will be 
identified with my approach. If a gene is carrying a mutation but is expressed at 
levels below the detection threshold in either the drug-resistant clone or the 
parental cell line, it will not be detected by the bioinformatics analyses. In order to 
detect rare transcripts the sequencing depth would need to be increased. 
An essential feature of my approach is conducting transcriptome 
sequencing of the parental cell line and using these data to identify mutations 
present only in resistant clones. The sequenced parental population should be as 
close as possible to the population of cells used for resistant selections. In my 
experiments with bortezomib I used a population of cells for selections that were 
many passages past the cells processed for RNA-seq (only one parental HCT-
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116 population – which was closest to the population selected with BI 2536 – 
was analyzed by transcriptome sequencing). I conjecture that this oversight is 
responsible for multiple genes being mutated in all bortezomib clones (Figure 
2.8b) and that the four non-PSMB5 genes were likely mutated with high 
frequency in the actual parental population. This prediction needs to be verified 
by analyzing the exact parental population used for bortezomib selection by 
RNA-seq. In future applications of this approach, heed should be taken to 
sequence the exact population of cells used for drug selection. 
 
Drugs with multiple targets 
A potential limitation of this approach to target identification is that it may 
be unsuccessful for compounds with more than one target; however, this 
depends upon the particular targets. If the targets are redundant, in that mutation 
of any target rescues cell growth, then sequencing a large number of clones 
would likely identify the targets. While this would require a significant research 
investment and the number of clones needed is unclear, our method should, in 
principle, be successful. 
In the case of a drug that causes toxicity through many distinct pathways, 
each target would need to be mutated to rescue growth. It is unlikely that 
mutations in all targets would occur simultaneously and, thus, it may be difficult to 
select for and obtain clones that had drug-specific resistance. I predict this is the 
case for ARQ-197, BE-54017, and Cladoniamide A, but further research is 
needed to test this hypothesis.  
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When a compound has multiple targets but only one of these results in cell 
death then only a mutation in this target would be required for resistance. In this 
scenario, only the cytotoxicity-conferring target would be detected.  
If a small molecule has multiple targets, but affects each target with a 
different potency, my method would likely only identify the most sensitive target. 
This is due to conducting selections with concentrations of compounds just high 
enough to kill most cells. However, if higher drug concentrations were used, it 
may be possible to identify more targets.  Interestingly, my proof-of-concept 
studies with bortezomib provide some insight into this issue. In addition to 
inhibiting PSMB5, bortezomib has been shown to inhibit PSMB1, another subunit 
of the proteasome, in cells (Berkers et al., 2005).  A brief examination of the 
other mutations identified in each clone (those which were not common to 
multiple independent clones), showed that PSMB1 is also mutated in two of the 
clones (A and D, Appendix 1, Tables A7 and A10). While I have not examined 
whether the PSMB1 mutation (R128H) confers resistance to bortezomib, or 
added resistance in a PSMB5 mutant background, its presence intimates that 
deeper analysis of the sequencing data obtained through our method might 
suggest secondary targets of a drug. In my study, bortezomib-resistant clones A 
and D, which contain the mutation in PSMB1, do not have altered LD50 values 
when compared with clones B and C (which contain only the A108T mutation in 
PSMB5, Figure 2.7b). Exploring whether or not the PSMB1 mutation affects the 




Expanding the scope of my approach 
In my proof-of-concept studies, I only conducted resistance selections 
based on cytotoxicity. Nevertheless, I do not believe my approach is limited to 
cytotoxic compounds. By using a mismatch repair deficient cell line, the parental 
population of cells has inherent genetic heterogeneity. Thus, phenotypic or 
reporter-based readouts could, in principle, be used to select clones with reduced 
drug response, eliminating the need to select for cell growth. High-throughput 
screens have been developed to identify small molecules that elicit a desired 
phenotype, such as the transcriptional activation of a luciferase reporter (Huang 
et al., 2009). These same systems should be able to select for drug-resistant 
clones when coupled with a cell sorting system (for example, fluorescent 
activated cell sorting).  Unfortunately, using a reporter-based readout would 
introduce bias into the approach, as only targets in the pathway resulting in 
activation of the reporter would be identified. Further experimentation is needed 
to confirm whether my target identification method can be used for non-cytotoxic 
drugs.  
My approach for target identification relies on transcriptome sequencing, 
which provides information on mutations in mRNA and changes in gene 
expression. In order to identify other potential mechanisms of resistance, such as 
mutations in promoter sequences and epigenetic changes, my strategy can be 
combined with other genomic methods, such as full genome sequencing, bisulfite 
conversion of unmethylated cytosines followed by sequencing to detect DNA 
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methylation, or chromatin immunoprecipitation followed by sequencing to 
evaluate transcription factor binding sites (Johnson et al., 2007; Laird, 2003).  
Genomics methodologies are rapidly advancing and becoming more accessible 
to general users (Wong et al., 2011). Thus, as research advances it will be 
beneficial to compare the various sequencing strategies and identify the most 
effective technologies for identifying resistance mechanisms.   
 In addition to coupling this method with other genomics technologies, I 
believe it would be beneficial to explore how to further utilize the transcriptome 
data. Currently, my approach systematically investigates coding mutations (single 
nucleotide variations and insertions/deletions) to identify those found in more 
than one independent clone. The gene expression data, however, were only 
examined after the mutation analysis did not identify a mechanism of resistance 
for all BI 2536-resistant clones. While the current bioinformatic strategy was able 
to successfully identify the known target of both BI 2536 and bortezomib, I feel 
that the overall approach may benefit from a systematic analysis of the gene 
expression data.  I envision analyzing the transcript abundance data in the same 
way as the single nucleotide variation data, by identifying genes up-regulated or 
down-regulated in more than one independent clone. However, it is not clear how 
great of a change in gene expression is necessary to be physiologically relevant. 
The current analysis reports on all genes with three-fold changes in expression 
compared to the parental population (Appendix 1, Tables A.12 – A.33). As each 
clone had 3 – 15-times more genes with altered transcript abundance than with 
single nucleotide variations, more research is needed to identify a gene-
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expression cut-off that is biologically meaningful and also tractable to 
bioinformatics analyses. Further research is also needed to identify a process for 
systematically analyzing the gene expression data.  
 
Advantages of my approach 
Even without additional technological or bioinformatics developments, the 
approach I have helped develop has several key advantages over other target 
identification methodologies. My approach allows for simultaneous identification 
of both drug targets and unrelated mechanisms of drug resistance in human 
cells. Unlike affinity-based approaches, this method can be used for drugs that 
are not very potent and the strategy does not rely on chemical modifications of 
the bioactive compound, which can alter its mechanism of action.  The approach 
should be able to analyze mechanisms of resistance in any human cell that can 
be grown in culture, enabling cell-type specific analyses. The strategy identifies 
targets without bias to any target class or pathway. Finally, the data provided by 
this method, when combined with biochemical analyses, identify targets with a 
level of proof that meets the gold standard of the field.  
 
Kinesin-5—small molecule interactions 
In chapter 3 I describe a method that incorporates heavy and light 
isotopes into small molecules to improve their detection after crosslinking to a 
protein. I use this strategy to investigate how the small molecule PCTP interacts 
with its target, kinesin-5.  
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Kinesins are motor proteins that can use ATP hydrolysis to drive 
movement along microtubules. A decade ago, the small molecule monastrol was 
found to inhibit the kinesin-5 protein (Mayer et al., 1999); this was the first 
chemical inhibitor that targeted a protein, other than tubulin, needed for mitotic 
spindle assembly. This discovery helped catalyze the development of drugs 
against kinesin-5, some of which are currently in clinical trials (Huszar et al., 
2009). Most kinesin-5 inhibitors, including monastrol and STLC, do not compete 
with ATP and bind to an allosteric region, called loop-5. These kinesin-5 inhibitors 
are also highly selective for kinesin-5. In contrast, PCTP and its close analogs 
have been shown to inhibit the kinesin proteins MCAK and Kif3A in addition to 
kinesin-5 (Rickert et al., 2008). My original goal was to improve the specificity of 
PCTP for kinesins other than kinesin-5. To accomplish this, I wanted structural 
information regarding the binding site of PCTP, which led to the development of 
the SILIC technique. 
The finding that PCTP crosslinks to the loop-5 binding site and is 
competitive with the loop-5 inhibitor STLC was surprising for two main reasons. 
First, most nucleotide-competitive inhibitors bind to the nucleotide-binding site, 
not a separate allosteric site (Zhang et al., 2009). Thus, I had expected to see 
PCTP crosslink to the ATP-binding pocket of kinesin-5. The second reason it was 
unexpected that PCTP crosslinked to the loop-5 pocket is that this loop is not 
conserved in other kinesins. The sequence of kinesin-5 contains an additional 5 – 
12 amino acids in loop-5 compared with other kinesins, indicating that the loop is 
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not as elongated in other kinesins, including MCAK and Kif3A, which are also 
sensitive to PCTP. This suggests that more studies are needed to determine how 
PCTP interacts with other kinesin proteins, particularly MCAK. These studies 
could also utilize the SILIC method. 
Interestingly, another ATP-competitive inhibitor of kinesin-5 has also been 
shown to bind outside of the nucleotide-binding pocket (Luo et al., 2007). GSK-1 
has been proposed to bind to an allosteric site that is distinct from the binding 
site of PCTP and STLC, based on a combination of resistant cell lines, site-
directed mutagenesis, and inhibitor crosslinking experiments. Further studies with 
both PCTP and GSK-1 are needed to reveal how binding at allosteric sites 
results in ATP-competitive inhibition that leads to a tightly bound microtubule-
motor protein complex. 
One approach to investigate how PCTP drives tight binding of kinesin-5 to 
microtubules is to examine mutations that affect the PCTP—kinesin-5 interaction. 
I identified two mutations in kinesin-5, Y104H and S269N, which were correlated 
with resistance to PCTP in human cells. Both mutations individually confer 
resistance to PCTP in the presence of microtubules in vitro. However, in the 
absence of microtubules these mutant proteins were not resistant to PCTP and 
one of the mutations, S269N, was more sensitive to the compound. The residues 
Y104 and S269 map together in the structure of kinesin-5 and are mostly 
conserved among kinesin proteins (Figure 3.12, Figure 4.1). I believe an 
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interesting area of further study would be examining how this site is important in 
PCTP inhibition of kinesin-5 and microtubule binding.  
I identified four mutations in kinesin-5 associated with resistance to STLC, 
but have not yet verified whether any of these mutations are sufficient to confer 
resistance to STLC. An initial examination of these mutations indicates that they 
are scattered throughout the kinesin-5 motor domain (Figure 4.2). Notably, one 
of the mutations associated with STLC resistance, A103V, is in the same region 
of the protein as the PCTP-resistant mutations. I believe all of these mutations 
warrant further investigation as they may lead to insights into the mechanism and 
regulation of kinesin-5 inhibitors. 
 
Perspective 
 While several approaches are available to identify the proteins a small 
molecule binds to and to characterize their interaction, they all have limitations. In 
my thesis work I developed two methods that overcome some of these 
limitations:  a chemical genetics strategy facilitates the identification of small 
molecule targets in human cells; and a method for characterizing drug-binding 
sites simplifies existing techniques that use small molecule crosslinking.  I expect 
these two approaches to become an important part of the chemical biology 









Figure 4.1 Clustal W alignment of kinesin sequences near kinesin-5 
residues Y104 and S269. The alignment uses sequences of selected kinesin 
family members. Kinesin-5, Kif3A, and MCAK are susceptible to inhibition by 
PCTP, while Kif1B, CENP-E, Kinesin-1, Kif5a, and MKLP1 are not targets of 








Figure 4.2 Location of kinesin-5 mutations associated with STLC 
resistance. The kinesin-5 ATPase domain (green, PDB: 2WOG) (Kaan et al., 
2010) in complex with ADP (orange) and STLC (blue). Residues A103, E123, 








Table A.1.1: Significant mutations identified in BI 2536-resistant clone A 








GNB2L1 C182Y 0/76 39/74 9.669E-12 
RPLP2 S86P 0/77 33/74 3.942E-09 
ACLY L998P 
L1008P 
0/45 25/41 1.967E-07 
NAMPT P417Q 0/41 26/44 7.503E-07 
EIF3L T354M 0/58 26/56 7.503E-07 
CAPN1 M594I 0/55 24/52 0.000002499 
VKORC1 F131S 0/46 21/41 0.000008499 
LTA4H P2S 0/42 16/27 0.00001429 
NDUFV2 V22I 0/40 16/31 0.0001378 
DPP7 D375V 0/41 16/32 0.0001594 
CTNNB1 T297M 0/44 15/32 0.0002658 
CCDC47 L163R 0/31 22/48 0.001517 
PLK1 R136G 0/43 15/39 0.002645 






Table A.1.2: Significant mutations identified in BI 2536-resistant clone B 








H1F0 P142L 0/63 33/66 0.000000018 
MAPK1IP1L S211L 0/34 20/33 0.00005697 
CALM2 G62S 0/54 22/55 0.00008785 
UBE2R2 D226N 0/41 20/40 0.0001057 
PLK1 R136G 0/43 18/38 0.0001766 
EPRS V530I 1/38 20/36 0.0003368 
KITLG K152N 0/50 19/49 0.0003368 
PPIH G175V 0/41 16/36 0.0008105 
EFTUD2 A511V 
A546V 






Table A.1.3: Significant mutations identified in BI 2536-resistant clone C 







GAL A39T 0/46 18/31 0.00001633 




1/50 22/45 0.0001135 
MCM5 R61W 0/36 17/36 0.001492 
PLK1 G63S 0/34 12/22 0.002141 
SCO2 R245I 0/27 11/17 0.002611 




Table A.1.4: Significant mutations identified in BI 2536-resistant clone D 















0/45 19/41 0.0001619 
PYCR1 A8D 0/46 17/39 0.0003439 
CHD4 G223R 0/48 13/28 0.0004466 
ARF3 A27T 0/39 16/34 0.0005887 




Table A.1.5: Significant mutations identified in BI 2536-resistant clone E 











0/51 23/51 0.00005968 
PYCR1 A8D 0/46 16/37 0.0008969 
ARF3 A27T 0/39 14/28 0.0009591 
TCF3 G302D 0/29 18/32 0.0009591 
TAPBP P149H 
P1141H 




0/45 16/40 0.001343 








1/41 14/28 0.003563 
LTBP3 S349Y 
S466Y 
0/37 13/29 0.003803 






Table A.1.6: Significant mutations identified in BI 2536-resistant clone F 










0/51 26/47 4.303 E-07 
ARF3 A27T 0/39 21/34 0.000004478 
KIAA2013 S379G 0/31 14/22 0.0003868 
CD151 Y62C 1/57 14/31 0.00106 















Table A.1.7: Significant mutations identified in bortezomib-resistant clone 
A 










0/58 45/89 1.575E-08 
PSMB1 R128H 0/56 42/83 3.583E-08 
CAPN1 R87C 0/37 45/77 6.763E-07 
PDCD6 R143W 0/38 35/68 0.00001485 
IER5L T266A 0/50 29/69 0.00003484 
SNAPC2 L126F 0/28 25/40 0.00008129 




1/50 34/80 0.000136 
NUMA1 P1932L 0/25 32/54 0.000208 
RRM1 P603H 0/40 30/70 0.0002232 
MKI67 F1438V 
F1798V 
0/41 25/57 0.0002376 
KIAA0664 L167P 0/37 26/56 0.0002484 
PPA2 M32T 0/32 18/32 0.0003507 
PTP4A1 R93C 0/38 33/80 0.0004211 
C11orf59 Y140N 1/37 34/70 0.0004873 
NCAPG A17G 1/37 13/20 0.0007323 




0/31 33/77 0.001635 
DHX38 P719T 0/22 27/49 0.002371 
PMPCB R238T 0/26 29/61 0.00284 
ARHGAP29 I77V 0/25 33/70 0.00327 
UBE2B W96R 0/23 28/55 0.003655 
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Table A.1.8: Significant mutations identified in bortezomib-resistant clone 
B 










0/58 47/93 9.671E-09 
IER5L T266A 0/50 39/78 3.606E-07 
MYH9 L906P 0/48 37/73 5.599E-07 
CAPN1 R87C 0/37 42/74 0.000001111 








0/31 45/85 0.00003752 
RRM1 P603H 0/40 28/59 0.0000583 
SFRS13A R590G 
R952G 
0/31 35/67 0.00007582 
KIAA0664 L167P 0/37 26/53 0.00008169 
PDIA4 A125V 0/52 29/85 0.0002119 
PPA2 M32T 0/32 18/32 0.0002535 
MKI67 F1438V 
F1798V 
0/41 22/51 0.0003204 
ETHE1 S19A 0/26 18/29 0.0004372 
AP1M2 F107L 0/23 40/72 0.0005007 
PDCD6 R143W 0/38 29/72 0.000577 
AP1M2 I109T 0/23 35/67 0.001409 
KIF1C R1030H 0/25 29/59 0.002085 
SPAG5 S353P 0/33 16/34 0.002085 
POLG A1105V 0/23 26/49 0.00212 
ARHGAP29 I77V 0/25 28/59 0.003322 
PPP1R10 R58H 0/22 32/63 0.003322 
MAST2 T652M 0/21 21/37 0.003405 




0/18 29/50 0.004052 
ABI2 R28W 0/19 23/40 0.004788 
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Table A.1.9: Significant mutations identified in bortezomib-resistant clone 
C 










0/58 34/63 2.582E-08 
PDCD6 R143W 0/38 27/45 0.000002127 
C19orf33 A39P 0/35 29/48 0.0000033 








1/50 26/57 0.0001033 
ID1 S8R 0/52 15/32 0.0001033 
IER5L T266A 0/50 16/35 0.0001141 
MKI67 F1438V 
F1798V 
0/41 19/42 0.0002948 
KIAA0664 L167P 0/37 15/28 0.0002948 
C11orf59 Y140N 1/37 26/51 0.0003872 
BAZ1B Y1358H 1/42 18/35 0.0004709 
SNAPC2 L126F 0/28 13/21 0.0007291 
ARHGAP29 I77V 0/25 28/55 0.001162 
PPP1R10 R58H 0/22 19/32 0.001423 
PPA2 M32T 0/32 11/20 0.001863 
PTTG1 T3N 1/34 16/30 0.002387 
PMPCB R238T 0/26 23/51 0.003889 
MRPL40 A161V 0/29 17/38 0.003892 
RRM1 P603H 0/40 16/46 0.004319 
PRNP C115G 
V115G 




Table A.1.10: Significant mutations identified in bortezomib-resistant clone 
D 










0/58 34/66 4.927E-08 
PSMB1 R128H 0/56 35/74 3.127E-07 
RRM1 P603H 0/40 25/41 0.000001578 
PTP4A1 R93C 0/38 37/67 0.000002102 
C19orf33 A39P 0/35 30/49 0.000002102 
PDCD6 R143W 0/38 27/49 0.000007936 
C11orf59 Y140N 1/37 29/50 0.00003677 








0/31 28/53 0.000119 
CAPN1 R87C 0/37 27/59 0.0001627 
KIAA0664 L167P 0/37 17/34 0.00034 
UBE2B W96R 0/23 27/46 0.000427 
PTTG1 T3N 1/34 14/21 0.000427 
NUMA1 P1932L 0/25 18/29 0.000427 
CDK5RAP3 V21G 0/33 13/22 0.000427 
SNAPC2 L126F 0/28 14/22 0.000427 
ARHGAP29 I77V 0/25 31/59 0.0005902 
MRPS35 C199Y 0/30 23/48 0.0008332 
PMPCB R238T 0/26 22/42 0.001105 
MKI67 F1438V 
F1798V 
0/41 15/36 0.001229 
PPA2 M32T 0/32 13/25 0.001465 
NOP14 T658M 0/24 15/26 0.002046 
DHX38 P719T 0/22 16/28 0.003174 
MARCH6 W783R 0/20 26/48 0.00318 








0/29 12/24 0.004292 
TUFM A6G 0/43 7/14 0.004936 
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Table A.1.11: Significant mutations identified in bortezomib-resistant clone 
E 








STT3A R662S 0/43 31/59 0.000001715 
CHD4 R1489H 1/43 33/58 0.000003451 
PSMB5 M1V 
M104V 
0/55 28/70 0.0000142 
PYCR1 S232N 0/57 25/73 0.0001192 
EGR1 P467T 0/38 36/86 0.0001875 
ITM2B A15T 0/29 26/48 0.000218 
NCAPH2 S63Y 0/27 17/30 0.001011 
PPP1R10 R58H 0/22 23/39 0.001151 
UBE2Z R321H 0/39 23/60 0.001302 
CDK5RAP3 V21G 0/33 15/30 0.001328 




0/47 12/29 0.001505 
ID1 S8R 0/52 14/41 0.001946 
ETHE1 S19A 0/26 9/13 0.002428 
STT3A V633A 0/43 20/61 0.00326 
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Studies toward the structural analysis of the kinesin-5–PCTP interaction 
My initial goal in studying the interaction of PCTP and kinesin-5 was to 
obtain a crystal structure of the protein—inhibitor complex. The kinesin-5 motor 
domain has been crystallized by several other groups both in the presence and 
absence of inhibitors (Kaan et al., 2010; Parke et al., 2010; Roecker et al., 2007; 
Turner et al., 2001; Yan et al., 2004). However, it had been reported that a group 
at Merck Research Laboratories was not able to solve the structure of the 
kinesin-5—PCTP complex (Rickert et al., 2008). As it was unlikely that I would be 
successful conducting crystallography studies where a large pharmaceutical 
company had failed, I decided to try another strategy. All published structures of 
kinesin-5 have been in the presence of nucleotide, either ADP or AMP-PNP (a 
non-hydrolyzable analog of ATP). Thus, I attempted to crystallize the PCTP—
kinesin-5 complex using two separate kinesin-5 samples: kinesin-5 bound to ADP 
and kinesin-5 in the absence of ADP (the apo-kinesin-5 protein). As PCTP is ATP 
competitive, I hoped that this dual strategy would be more successful in 
generating structures of the protein—inhibitor complex.  
To obtain apo-kinesin-5 protein, the kinesin-5 protein was purified in the 
absence of ATP and MgCl2, which are typically included in kinesin purification 
buffers. The protein was also incubated with relatively high concentrations of 
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EGTA and EDTA, with the goal of chelating residual Mg ions and destabilizing 
ADP that was bound to kinesin-5. This procedure, which was based on published 
results (Cochran and Gilbert, 2005), produced kinesin-5 that, when examined by 
native mass spectrometry, was consistent with it being the apo form of the 
protein (Figure A.2.1). I have not, however, fully determined whether this apo-
kinesin-5 protein is homogeneously lacking nucleotide. 
 Large quantities of the kinesin-5 motor domain were purified both bound to 
ADP and with an empty nucleotide-binding pocket. Crystallization trials were 
conducted with both constructs using published kinesin crystallization conditions 
and standard sparse-matrix crystallization screens. From previously published 
kinesin-5 conditions, I obtained imperfect crystals of kinesin-5 with ADP, but not 
with apo-kinesin-5 (Figure A.2.2a). Microseeding from the original crystals was 
conducted in order to generate single crystals of kinesin-5 with ADP (Figure 
A.2.2b).  These crystals diffracted below 2.8 Å on the Rockefeller Structural 
Biology Resource Center beamline; however, these crystals were never used to 
solve a structure as the kinesin-5—ADP structure has already been published 
(Turner et al., 2001). These crystals could potentially be used for soaking with 
PCTP to determine if it is possible to obtain a structure of the kinesin-5—PCTP 
complex. No crystals were obtained under any condition with the apo-kinesin-5 
protein. Furthermore, when PCTP was added to the crystallization wells with 
kinesin-5—ADP, crystals did not form. These trials suggest that it will be difficult 






Figure A.2.1 Native mass spectrometry of kinesin-5. (a) Native mass 
spectrum of kinesin-5 with ADP (z = 11). The 3742.2 peak represents the mass 
of kinesin-5 alone (41,164 Da), while the 3781.0 peak represents kinesin-5 bound 
to ADP (41591 Da). (b) Native mass spectrum of apo-kinesin-5 (z = 11). The 
3742.5 peak represents the mass of kinesin-5 alone (41,167 Da). Native mass 









Figure A.2.2 Crystallization of kinesin-5 with ADP. (a) Crystals of kinesin-5 
with ADP grew in hanging drops using 1:1 parts well buffer (100 mM MES, pH 
5.5 – 6.0, 21 – 24% PEG 3350, and 200 mM NaNO3) and protein (7 – 14 mg/ml) 
at 4°C. (b) Single crystals of kinesin-5 with ADP grew from microseeds of 
previous crystals in hanging drops using 1:1 parts well buffer (100 mM MES, pH 





Studies toward the structural analysis of the kinesin-5 S269N mutant 
 In order to better characterize the effects of mutation in the region of 
kinesin-5 that contains residues Y104 and S269, crystallization of the kinesin-5 
S269N motor domain was attempted. The kinesin-5 S269N protein (bound to 
ATP) formed crystals in similar conditions as the wild type kinesin-5, after 
seeding with kinesin-5 microseeds (Figure A.2.3). Initially kinesin-5 wild type 
microseeds were used; the wild type protein was then diluted with a second 
round of microseeding using the kinesin-5 S269N crystals. Kinesin-5 S269N 
crystals consistently formed clusters that were difficult to break apart.  
 A full data set from kinesin-5 S269N that diffracted below 2 Å was 
collected at the National Synchrotron Light Source at the Brookhaven National 
Laboratories. With the help of Deena Oren at Rockefeller’s Structural Biology 
Resource Center, I used these data to solve the structure of kinesin-5 S269N 
using molecular replacement of the wild type kinesin-5 structure (Turner et al., 
2001). The structure is partially refined and currently has an Rfree factor of 
25.13% (Table A.2.1). The electron density map of kinesin-5 S269N is consistent 
with the protein containing the mutated residue (Figure A.2.4a). With minimal 
further refinement, this structure is suitable to be deposited in the Protein Data 
Bank. In comparing my structure of kinesin-5 S269N with the published structure 
of kinesin-5 wild type the main variations are in loops with high B factors that are 
presumed to have some inherent flexibility (Figure A.2.4b). I could not detect any 












Figure A.2.3 Crystallization of kinesin-5 S269N with ADP. Crystals of kinesin-
5 S269N with ADP grew from kinesin-5 microseeds in hanging drops using 1:1 
parts well buffer (100 mM MES, pH 5.5, 16 – 20% PEG 3350, and 100 – 300 mM 






Table A.2.1 Data collection and refinement statistics for kinesin-5 S269N 
structure. This structure may need further refinement. 
 
Collection  
   Synchrotron NSLS 
   Beamline X29A 
   Space Group P21 
   a, b, c, ß (°) 52.38, 78.22, 92.58, 93.06 
   Resolution (Å) 50.0 – 1.95 (2.01 – 1.95) 
   Rsym (%) 9.6% (53.6%) 
   <I/s(I)> 17.5 (3.6) 
   Observed reflections 125,417 
   Unique reflections 54,417 
   Completeness  99.8% (100%) 
   Redundancy 6.2 
Refinement  
   r.m.s.d. bond lengths (Å) .0138 
   r.m.s.d. bond angles (°) 1.630 
   Rfactor (%) 19.70% 
   Rfree (%) 25.13% 












Figure A.2.4 Structure of kinesin-5 S269N. (a) The electron density map of 
kinesin-5 S269N is consistent with residue 269 being an asparagine.  (b) An 
alignment of kinesin-5 wild type (PDB: 1II6, green) (Turner et al., 2001) and 






Materials and Methods 
 
Cell culture conditions 
 HCT-116 cells and clonal lines were cultured in McCoy’s 5A medium 
(Invitrogen). hTERT-RPE1 cells were cultured in Dulbecco's Modified Eagle's 
Medium/F12 1:1 nutrient mix (Invitrogen), while HeLa and 293-Ampho cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (Invitrogen). All cultures were 
supplemented with 10% FBS (Atlanta Biologicals) and penicillin-streptomycin 
(100 U/ml and 100 ug/ml, respectively, Invitrogen) and grown at 37°C in a 
humidified chamber with 5% CO2. hTERT-RPE1, HeLa, and 293-Ampho cells 
were also supplemented with 1% MEM non-essential amino acids (Invitrogen) 
and 2 mM l-glutamine (Invitrogen).   
 
Molecular biology and cloning 
 Human PLK1 (image clone ID# 2822226, Open Biosystems) or human 
PSMB5 (image clone ID# 4795732, Open Biosystems) was cloned into a 
pMSCV_puro vector (Clontech) with an N-terminal GFP – PreScission protease 
site compatible with the Gateway cloning system (Invitrogen). Site-directed 
mutagenesis to generate the PLK1 R136G and G63S mutations or the PSMB5 
M104V and A108T mutations was performed using QuickChange (Stratagene) 
according to the manufacturer’s instructions. DNA encoding the wild type and 
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mutant proteins was used to generate stable cell lines through retroviral infection. 
Retroviruses were packaged in 293-Ampho cells. hTERT-RPE1 and HeLa cells 
were infected by retrovirus with 4 μg/ml polybrene (Sigma) and selected by 
puromycin (Sigma).  
The human kinesin-5 ATPase domain (residues 1-368, Pubmed 
accession: NP_004514 from Open Biosystems) was cloned into a pET28a vector 
containing a PreScission protease cleavable N-terminal His-tag. This adds a ‘GP’ 
sequence at the N-terminus of the native protein sequence after removal of the 
His tag by PreScission proteolysis. The L214A, Y104H, and S269N mutant was 
generated from this plasmid using QuickChange site-directed mutagenesis kit 
(Stratagene). For in vitro experiments, the full-length human Plk1 wild type and 
G63S mutant proteins were also cloned into pFastbac Htb baculovirus 
expression vectors (Gibco) with a TEV protease cleavable N-terminal His-tag. 
 
Preparation of fixed cells and imaging 
 For microscopy, cells were plated on glass coverslips coated with poly-D-
lysine (Sigma). The following day, cells were incubated in media containing 
DMSO or 50 nM BI 2536 for 5 hours in standard culture conditions. Cells on 
coverslips were fixed in methanol at -20°C for ten minutes and washed in TBS-Tx 
(TBS with 0.1% Triton-X-100) before they were blocked in AbDil (TBS-Tx with 1% 
BSA) for one hour at room temperature. Cells were stained with FITC-conjugated 
anti-tubulin DM1a antibody (Sigma) at a dilution of 1:1500 in AbDil and Hoescht. 
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Fixed cells were imaged with a Nikon TE2000 microscope (Morrell Instruments) 
or a DeltaVision Image Restoration Microscope (Applied Precision Instruments) 
and deconvoluted in SoftWoRx.  
 
Chemical compounds 
 BI 2536 ( > 99% pure) was purchased from Selleck chemicals. Bortezomib 
(99% pure) was purchased from LC Laboratories.  S-trityl-L-cysteine (STLC, 97% 
pure) and taxol ( > 95% pure) were purchased from Sigma.  Hesperadin ( > 95% 
pure), 4-(2-(1-phenylcyclopropyl)thiazol-4-yl)pyridine (PCTP, > 95% pure) and 
PCTP analogs 1 and 2 (both > 95% pure) were synthesized by a lab member, 
Sudhir Kashyap (Wacker et al., 2011). ARQ-197 ( > 98% pure) was purchased 
from Active Biochemicals. BE-54017 and Cladoniamide A were obtained from 
Fang-Yuan Chang. 
 
Selection of resistant clones 
 Resistant clones were generated by plating 0.5 – 1.0 x 106 HCT-116 cells 
into 10 cm culture dishes with media containing 10 nM BI 2536, 1 μM STLC, 8 – 
12 μM PCTP, 8 – 12 nM bortezomib, 0.1 – 3 μM hesperidin, 2.5 – 7.5 nM taxol,  
750 – 850 nM ARQ-197, 200 – 400 ng/ml BE-54017, or 150 – 200 ng/ml 
Cladoniamide A. Drug concentrations were determined by either using the LD90 
or experimentally determining a concentration of drug that killed all cells except a 
few which would grow into colonies. After cells had adhered, media with 
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compound was exchanged every three days for three - five weeks. Most cells did 
not survive, but a few per plate grew into colonies (less than 20 colonies were 
found on each plate). Colonies were picked by placing a cloning cylinder around 
each clone and then treating with 50 μl 0.05% trypsin-EDTA for five minutes. 
Cells were then transferred to a single well of a 24-well plate containing media 
with compound. As cells became confluent they were transferred to larger culture 
dishes, always with media containing drug at the same concentration as the 
selections.  
 
Cell proliferation assays and calculation of LD50 values 
 In order to quantify cell growth in the presence of drug, cells (1000 in 100 
μl of media per well) were plated in a flat-bottomed 96-well plate and treated the 
next day with various concentrations of the appropriate compound, in duplicate. 
After three days, cell proliferation was determined using a WST1 assay 
(Millipore) according to the manufacturer's instructions. Normalized cell 
proliferation was calculated as the change in the number of cells at each 
concentration compared to control wells. The assay was repeated two - six 
independent times. Normalized cell proliferation values were plotted and LD50 
values were obtained by curve fitting with Prism. A two-tailed paired t-test was 




RNA purification and RT-PCR 
 Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer's instructions. Full-length Plk1 or kinesin-5 cDNA 
was synthesized and amplified from total RNA using Plk1 or kinesin-5 specific 
primers and the SuperScript III One-Step RT-PCR System (Invitrogen).  
 
RNA-seq library construction  
 Following isolation, total RNA integrity was checked using an Agilent 
Technologies 2100 Bioanalyzer and an RNA Integrity Number greater than 8 was 
required for further processing. Library construction was performed according to 
standard Illumina protocols with Illumina reagents. Briefly, mRNA was purified 
from total RNA using magnetic beads: 5-100 ng of total RNA were heated to 
disrupt the secondary structures and then added to pre-prepared Sera-mag 
Magnetic Oligo(dT) Beads. After washing, 10mM Tris-HCI was added to the 
beads, the samples were heated, and mRNA was eluted. The mRNA was then 
fragmented using divalent cations under elevated temperatures. The cleaved 
RNA fragments were copied into first strand cDNA using reverse transcriptase 
and random primers. mRNA was removed by RNaseH and a replacement strand 
was synthesized to generate double-strand cDNA. The overhangs resulting from 
fragmentation were converted into blunt ends by T4 DNA polymerase and DNA 
polymerase I Klenow fragment. An ‘A’ base is added to the 3' end of the blunt 
phosphorylated DNA fragments to prepare them for ligation to the adapters, 
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which have a single ‘T’ base overhang at their 3' end. Illumina adapters were 
ligated to the ends of the DNA fragments, preparing them to be hybridized to a 
flow cell. Ligation reaction products were purified on an agarose gel. A 200 ± 25 
bp size-range of templates was selected for downstream enrichment. The cDNA 
fragments with adapters on both ends were amplified by PCR with primers 
complementary to the adapters. Size, purity and concentration of the library were 
checked on an Invitrogen Qubit Fluorometer using the Quant-IT dsDNA HS 
Assay Kit and on an Agilent Technologies 2100 Bioanalyzer using their High 
Sensitivity DNA Kit. 
 
High-throughput sequencing 
 Sequencing was performed using both Illumina GAIIx (for BI 2536 clones) 
and HiSeq2000 (for bortezomib clones) machines. For GAIIx, the protocols for 
the Illumina Single-Read Cluster Generation Kit were used for cluster generation 
on the Cluster Station. The targeted samples were diluted to ten nanomoles and 
denatured with sodium hydroxide.  Ten picomoles of each target-enriched 
sample and control was loaded into separate lanes of the same flow cell, 
hybridized onto the flow cell, and isothermally amplified.  After linearization, 
blocking, and primer hybridization, sequencing was performed for 40 cycles on 
the Illumina 36 Cycle Sequencing Kit v4 with version 7.0 sequencing protocols.  
Raw image data was converted into base calls using the Illumina pipeline v1.6 
with default parameters.  Rigorous quality control was performed using data from 
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reports generated by the Illumina pipeline. For HiSeq2000, a similar protocol was 
used, and some of the clones were sequenced on the same lane (3-plex). After 
quantifying and checking the size and purity of the product, multiplexed DNA 
libraries were normalized to 10 nM and then sample libraries were pooled 
together in equal volumes. 7 pM of each pooled DNA library template was 
amplified on an Illumina cBot instrument involving immobilization and 3’ 
extension, bridge amplification, linearization and hybridization, then sequenced 
on the Illumina HiSeq2000 sequencer using 51 cycles. 
 
Alignment of RNA-seq reads 
 RNA-seq reads were aligned to RefSeq transcript sequences downloaded 
from the UCSC Genome Browser in June 2010, using the BWA program with 
default parameters (Li and Durbin, 2009). Out of 25-100 million reads obtained in 
each run, 74-83% could be mapped to RefSeq transcripts. Clonal reads, i.e. 
multiple reads mapping at the same position and same orientation in a transcript, 
were collapsed into a single read (Chepelev et al., 2009). Following mapping to 
RefSeq transcripts to identify reads mapping to exons and across known exon 
junctions, all mapped reads were remapped to the reference human genome 





Overall bioinformatics strategy 
 The following strategy was used to determine which genetic variants 
increased their relative abundance in the expanded clones compared to the 
original cell population. First, single nucleotide variations (SNVs) and 
insertions/deletions (indels) in the sequenced mRNAs of each clone were 
identified. Next, the relative abundance of these variants was compared to the 
relative abundance in the same variants (at the same location) in the original cell 
population. Only variants whose relative abundance had increased significantly 
(after correction for multiple hypothesis testing) in the expanded clone were 
retained. Finally, variants with unlikely functional impact, e.g. synonymous 
variants and variants in 5’UTRs and 3’UTRs were filtered out. All bioinformatics 
analyses were conducted by my collaborator, Olivier Elemento. All computer 
programs and scripts used for the analysis, together with a comprehensive 
description of how to use them are available at his website: 
http://icb.med.cornell.edu/wiki/index.php/Elementolab/TargetID 
 
Expression and purification of full-length Plk1 
Full-length Plk1 was produced in Sf9 insect cells through a baculovirus 
expression system. Cells were resuspended in buffer containing 50 mM 
phosphate (pH 8), 300 mM KCl, 10 mM imidazole, 0.1% Tween-20, 10% glycerol, 
5 mM MgCl2, 1 mM ATP, and HALT protease inhibitor cocktail (Pierce), then 
lysed by sonication. The lysate was clarified by centrifugation and applied to Ni-
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NTA resin (Qiagen). Resin was further washed with a buffer containing 50 mM 
phosphate (pH 8), 250 mM KCl, 20 mM imidazole, 10% glycerol, 1 mM MgCl2, 50 
μM ATP, and HALT. Protein was eluted from the Ni-NTA resin using the same 
buffer as the wash steps but that contained 250 mM imidazole and 150 mM KCl.  
Samples containing protein were identified with a Bio-Rad protein assay and then 
combined. The protein sample was combined with AcTEV protease (20 units, 
Invitrogen) and then dialyzed into Plk1 storage buffer containing Protein was 
concentrated and dialyzed into buffer containing 10 mM HEPES (pH 7.5), 150 
mM KCl, 10 mM MgCl2, 10% sucrose and 500 μM dithiothreitol. 
 
Kinase assay 
Plk1 activity was assayed in kinase buffer (20 mM HEPES (pH 7.5), 10 
mM MgCl2, 5 mM dithiothreitol, 1 mM EGTA, 10 mM NaF, and 20 mM β-
glycerophosphate). Casein (3 μg), recombinant full-length human Plk1, and the 
appropriate amount of compound in DMSO (5% (v/v) final) were added to half the 
reaction volume (10 μl) and allowed to incubate for 15 min on ice. Then 10 μl of 
kinase buffer containing 150 μM [γ-32P]ATP was added. Reactions were mixed, 
incubated for 20 min at 30°C and stopped by the addition of Laemmli sample 
buffer and heating at 80°C for ten minutes. Proteins were resolved by SDS-PAGE 
(4-20% tris-glycine gel). Gels were dried and visualized by autoradiography. Gel 
bands were quantified with ImageJ software (National Institute of Health).  
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Expression and purification of kinesin-5 
Expression of kinesin-5 motor domain in Escherichia coli BL21(DE3) 
Rosetta cells (Novagen) was induced with 0.5 mM isopropyl-1-thio-β-d-
galactopyranoside. After growth at 18°C for 16 – 22 hours, cells were harvested. 
Cells were resuspended in buffer containing 50 mM phosphate (pH 8), 250 mM 
KCl, 7.5 mM imidazole, 0.1% Tween-20, 0.5 mM MgCl2, 0.5 mM ATP, 10 mM β-
mercaptoethanol (BME), 2 mM benzamidine-HCl, 1 mM phenylmethanesulfonyl 
fluoride (PMSF), and HALT protease inhibitor cocktail (Pierce), then lysed by 
sonication. The lysate was clarified by centrifugation and applied to Talon resin 
(Clontech). Resin was further washed with the lysis buffer before protein was 
removed from the column by overnight cleavage at 4°C with GST-PreScission 
protease. After cleavage, the sample was incubated with glutathione resin to 
remove PreScission protease. Kinesin-5 protein was concentrated and dialyzed 
into crystallization buffer (50 mM Pipes (pH 6.8), 50 mM KCl, 0.2 mM MgCl2, 0.1 
mM ATP, 1 mM EGTA, and 0.1 mM Tris-(2-carboxyethyl)phosphine (TCEP) HCl). 
Wild type kinesin-5 and kinesin-5 S269N for crystallography studies were further 
purified by size exclusion chromatography (Superdex 200; Amersham Pharmacia 
Biotech) before the dialysis step. Samples for ATP hydrolysis assays and 
crystallography were stored at -80°C until needed. 
Apo-kinesin-5 was expressed as above with a few modifications. Cells 
were resuspended in buffer containing 50 mM phosphate (pH 8), 250 mM KCl, 
7.5 mM imidazole, 0.1% Tween-20, 10 mM BME, 2 mM benzamidine-HCl, 1 mM 
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PMSF, and HALT protease inhibitor cocktail (Pierce). After binding to the TALON 
resin, subsequent cleavage with PreScission protease, and removal of 
PreScission protease, the kinesin-5 protein sample was incubated with a final 
concentration of 5 mM EDTA and 5 mM EGTA for 30 minutes. Afterwards EDTA 
and EGTA were removed by dialysis into “apo crystallization buffer” (50 mM 
Pipes (pH 6.8), 50 mM KCl, 1 mM EGTA, and 0.1 mM TCEP-HCl). 
Full-length Xenopus laevis kinesin-5 used in the microtubule gliding 
assays was prepared as described previously (Weinger et al., 2011). Bovine 
tubulin was purified and labeled with X-Rhodamine according to published 
protocols (Hyman, 1991). 
 
Steady-state ATP hydrolysis and microtubule motility assays  
For steady-state ATP hydrolysis assays and crosslinking experiments, 
microtubules were polymerized from recycled tubulin in BRB80 buffer (80mM 
Pipes (pH 6.8), 1 mM MgCl2, 1mM EGTA) containing 10% DMSO, 1 mM 
dithiothreitol, and 1 mM GTP at 37°C for 25 min. Microtubules were pelleted over 
a 40% glycerol cushion and resuspended in BRB80 with 20 μM taxol.  
ATP hydrolysis experiments used an assay that coupled ATP hydrolysis to 
oxidation of NADH (De La Cruz et al., 2000). Reactions were performed in 
BRB80 (reactions with microtubules) or 200 mM potassium phosphate (pH 8, 
reactions without microtubules) along with 1 mM dithiothreitol, 0.1 mg/ml bovine 
serum albumin (Fisher Scientific), 2.5% DMSO, 1 mM MgATP, 2.5 mM reduced 
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β-Nicotinamide adenine dinucleotide (disodium salt, Sigma), 200 U/ml L-lactic 
dehydrogenase (from rabbit muscle, Sigma), 1000 U/ml pyruvate kinase (from 
rabbit muscle, Sigma), 5 mM Phospho(enol)pyruvic acid (monopotassium salt, 
Sigma), and 400 nM  microtubules. Kinesin-5 motor domain was added to begin 
reactions, which were conducted in 50 μl volumes in 384-well plates. Time 
courses of fluorescence decrease upon NADH oxidation were obtained using a 
FlexStation microplate reader (λex = 340 nm, 440 nm emission filter). Normalized 
specific activity values were plotted and IC50 values were obtained by curve fitting 
with either Kaleidagraph or Prism.  
For microtubule gliding assays, X-Rhodamine labeled microtubules were 
polymerized from GMPPCP seeds in BRB80 and stabilized with 10 μM taxol.  
Microtubule gliding assays were performed using TIRF microscopy on an 
inverted microscope (Axiovert; Carl Zeiss) (Kapitein et al., 2008) and conducted 
as described previously (Kwok et al., 2004). 
 
Photo-crosslinking reactions  
PCTP analogs 1 and 2 (40x final, in DMSO) were combined with kinesin-5 
ATPase domain (1.5 μM) in 50 mM HEPES (pH 7, no microtubules) or in BRB80 
with 3.3 μM microtubules (polymerized as in the ATP hydrolysis assays). 
Samples were irradiated at 254 nm using a Spectroline ENF 260C UV lamp for 
30 min at 4°C (no microtubules) or room temperature (with microtubules). 
Reactions were stopped by the addition of dithiothreitol (12.5 mM final) and gel 
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loading buffer. For competition experiments, 1 was pre-mixed with PCTP or 
STLC in DMSO to obtain a 40x solution of each compound. 
 
Sample preparation for mass spectrometry 
Crosslinked samples, combined with gel loading buffer and dithiothreitol, 
were briefly heated (10 min, 70°C), and then treated with iodoacetamide (125 
mM) for 30 min to alkylate all reduced cysteines. Proteins were separated and 
immobilized on Bis-Tris gels (Invitrogen), followed by fixation in a 50% 
methanol/7% acetic acid solution. Protein bands were visualized by GelCode 
Blue stain (Pierce). Kinesin-5 bands were excised from the gel, sliced, and 
destained in 50 mM ammonium bicarbonate/50% acetonitrile for 30 min. Gel 
slices were then dehydrated in acetonitrile (HPLC-grade, Pierce) for 10 min. The 
dried gel slices were rehydrated in 25 mM ammonium bicarbonate with 125 ng 
trypsin (Promega) for protein digestion at 37°C overnight. The resulting peptides 
were enriched with StageTips (Rappsilber et al., 2007). The peptides eluted from 
the StageTips were dried down by SpeedVac and then resuspended in 0.5% 
acetic acid for analysis by LC-MS/MS. 
 
Mass spectrometry 
Mass spectrometry was performed by Xiang Li on an LTQ-Orbitrap XL 
mass spectrometer (Thermo Fisher Scientific), using a home-built micro 
electrospray source with a liquid junction. First, peptide samples in 0.5% acetic 
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acid were pressure loaded onto a self-packed PicoFrit column (New Objective) 
with integrated emitter tip (360-mm o.d., 75-mm i.d., 15-mm tip), packed with 6 
cm of reverse-phase C18 material (Alltima C18 5-mm beads from Alltech 
Associates), rinsed for 10 min with 0.1 M acetic acid and subsequently gradient 
eluted with a linear gradient from 0 to 100% B in 30-50 min (A = 0.1 M acetic acid, 
B = 70% acetonitrile in 0.1M acetic acid, flow rate 200 nL/min) into the mass 
spectrometer. The instrument was operated in a data dependent mode cycling 
through a full scan (300–2,000 m/z, single mscan) followed by 7 CID MS/MS 
scans on the 7 most abundant ions from the immediate preceding full scan. The 
cations were isolated with a 2-Da mass window and set on a dynamic exclusion 
list for 60 seconds after they were first selected for MS/MS. The raw data were 
analyzed by Quant module of MaxQuant (Cox and Mann, 2008; Cox et al., 2009) 
to find peptide pairs with a 4 Da mass difference. 
 
Crystallography of kinesin-5 
Kinesin-5 (apo, wild type with ADP, or S269N with ADP) was concentrated 
to 14 – 25 mg/ml in crystallization buffer or “apo crystallization buffer.” Kinesin-5 
was crystallized by hanging drop vapor diffusion at 4°C using an equal volume of 
protein sample (protein was diluted to 3.5 – 14 mg/ml) and crystallization solution 
consisting of 0.1 M MES (pH 5.5 – 6.0), 14 – 24% PEG 3350, and 100 – 300 mM 
NaNO3. Crystals appeared in 1 – 2 weeks. Microseeding was used to obtain 
cleaner crystals. For data collection, crystals were flash-frozen in liquid nitrogen 
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after a brief soak in a solution comprising of 0.1 M MES (pH 5.6), 22% PEG 
3350, 200 mM NaNO3, and 15% glycerol.  
Diffractions datasets of kinesin-5 S269N crystals were collected at the 
National Synchrotron Light Source (Brookhaven National Laboratory) beamline 
X29a. Diffraction data was processed using HKL2000 and phase information was 
obtained through molecular replacement with the program Phaser using the 
structure of wild type kinesin-5 (PDB: 1II6) (Turner et al., 2001). Refinement was 
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